1 
 Mutations in Rv2983 as a novel determinant of resistance to nitroimidazol e drugs in
Mycobacterium tuberculosis
Dalin Rifat1,S i - Y a n gL i1, Thomas Ioerger2, Jean-Philippe Lanoix3, Jin Lee1, Ghader Bashiri4,
James Sacchettini5and Eric Nuermberger1,*
1Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1550
Orleans Street, Baltimore, MD 21287, USA
2Department of Computer Science, Texas A&M University, College S tation, TX, 77843, USA
3Department of Infectious Diseases, Amiens University Hospital, Amiens, France
4Laboratory of Structural Biology and Maurice Wilkins Center for  Molecular Biodiscovery,       
School of Biological Sciences, University of Auckland, Auckland  1010, New Zealand
5Department of Biochemistry and Biophysics, Texas A&M University , College Station, TX,     
77843, USA
*Corresponding author. Email: enuermb@jhmi.edu     Tel: 410-502-7683
SIGNIFICANCE
Nitroimidazole pro-drugs represent a promising new class of anti-tuberc ulosis drugs. Reliable
methods to assure nitroimidazole susceptibility are critical to assure t heir optimal use. Yet, the
spectrum of nitroimidazole resistance mutations remains incompletely c haracterized. Using 161
pretomanid-resistant Mycobacterium tuberculosis isolates selected in pretomanid-treated mice,
we discovered a novel resistance determinant, Rv2983 , required for cofactor F 420biosynthesis
and characterized the remarkable diversity of mutations in this and 5 othe r genes involved incertified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 2 
 nitroimidazole activation. We show that F 420H2‚Äìdeficient nitroimidazole-resistant mutants are
hypersusceptible to the selective decontaminant malachite green used in solid media to isolate
mycobacteria and may evade detection on such media. These results have imp ortant implications
for development and clinical use of genotypic and phenotypic methods for n itroimidazole
susceptibility testing.
ABSTRACT
Delamanid represents one of two novel antimicrobial classes approved to treat tuberculosis in
over 40 years. Pretomanid is another promising nitroimidazole pro-drug in clinical development.
Characterization of the full spectrum of mutations conferring res istance to nitroimidazoles and 
their related phenotypes in Mycobacterium tuberculosis will inform development of suitable 
genotypic and phenotypic drug susceptibility tests. Here, we used a range of pretomanid doses
to select pretomanid-resistant mutants in two pathologically dis tinct murine TB models. The 
frequency of spontaneous pretomanid resistance mutations was ap proximately 10-5CFU.
Pretomanid demonstrated dose-dependent bactericidal activity and  selective amplification of 
resistant mutants. Whole genome sequencing of 161 resistant isolates from 47 mice revealed 99
unique mutations, 90% of which were found in 1 of 5 genes previo usly associated with 
nitroimidazole activation and resistance. The remaining 10% harbor ed isolated mutations in 
Rv2983 . Complementing an Rv2983 mutant with a wild-type copy of Rv2983 restored wild-type 
susceptibility to pretomanid and delamanid, confirming that loss of Rv2983 function causes
nitroimidazole resistance. By quantifying F 420and its precursor Fo in Mycobacterium smegmatis
overexpressing Rv2983 and an M. tuberculosis Rv2983 mutant, we provide evidence that Rv2983
is necessary for F 420 biosynthesis and nitroimidazole activation, perhaps as the 
guanylyltransferase CofC. F 420H2-deficient mutants displayed hypersusceptibility to malachite 
green (MG), a selective decontaminant present in solid media used to isolate and propagate 
mycobacteria from clinical samples. The wide diversity of mutatio ns causing high-level certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 3 
 pretomanid resistance and MG hypersusceptibility of most mutants poses significant challenges
to clinical detection of nitroimidazole resistance using either gen otypic or phenotypic methods. 
INTRODUCTION
Despite decades of efforts to end the global tuberculosis (TB) e pidemic, Mycobacterium 
tuberculosis is the leading killer among infectious agents plaguing mankind ( 1). The emergence 
and spread of multidrug-resistant (MDR) and extensively drug-re sistant (XDR) M. tuberculosis
makes the eradication effort much more difficult because treatment  requires administration of 
more toxic and less effective second- and third-line drugs for u p to 2 years ( 1, 2). Delamanid and 
pretomanid are promising new bicyclic 4-nitroimidazole drugs that have shown potential in pre-
clinical and clinical studies to shorten and simplify the treatment of TB, including drug-resistant 
forms ( 3-9). Delamanid received conditional approval by the European Medic ines Agency (EMA) 
to treat MDR-TB in 2014 ( 10) and pretomanid is currently being evaluated in Phase 2/3 clinical  
trials ( ClinicalTrials.gov Identifiers: NCT03338621, NCT02589782, NCT0233 3799,
NCT03086486 ). Particularly notable is a novel regimen comprised of bedaquili ne, pretomanid 
and linezolid that may represent a highly efficacious oral, shor t-course regimen for treatment of 
MDR/XDR-TB ( 4)(ClinicalTrials.gov Identifiers: NCT02333799, NCT03086486) .
Two non-exclusive mechanisms of action have been described for th ese bicyclic 4-nitroimidazole
drugs: inhibition of cell wall biosynthesis through inhibition of my colic acid synthesis and 
respiratory poisoning through release of nitric oxide during bac terial drug metabolism ( 11, 12 ).
Pretomanid and delamanid are prodrugs that require bioreductive activation of an aromatic nitro 
group by the 8-hydroxy-5-deazaflavin (coenzyme F 420)-dependent nitroreductase Ddn in order to 
exert bactericidal activity ( 13). The reaction involves the transfer of two electrons from the reduced 
form of F 420(F420H2) produced by an F 420-dependent glucose-6-phosphate dehydrogenase (Fgd1)
(12, 14 ). Therefore, F 420biosynthesis and reduction are essential for the activation of de lamanid, 
pretomanid and other nitroimidazole prodrugs. Three genes are ide ntified as essential for F 420certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 4 
 biosynthesis in M. tuberculosis complex ( 15, 16 ).fbiC encodes a 7,8-didemethyl-8-hydroxy-5-
deazariboflavin (Fo) synthase that catalyzes the condensation of 5- amino-6-ribitylamino-2,4 (1 H,
3H)-pyrimidinedione and tyrosine to form the F 420precursor Fo ( 17, 18 ).fbiA encodes a
transferase that is believed to catalyze the transfer of a phospholactyl moiety to Fo to generate 
F420-0, while fbiBencodes a F 420-»ñ-L-glutamyl ligase that catalyzes the sequential addition of a
variable number of glutamate residues to F 420-0 to yield coenzyme F 420-5 or -6 in mycobacteria 
(12). In the methanogen Methanocaldococcus jannaschii , a guanylyltransferase termed CofC is 
believed to generate an intermediate (L-lactyl-2-diphospho-5‚Äô-guanosine, LPPG) in the F 420
biosynthesis pathway ( 19). A homologous enzyme, MSMEG_2392, is shown to be necessary for 
F420synthesis in Mycobacterium smegmatis through transposon mutagenesis studies ( 20). An
ortholog, Rv2983 , is present in M. tuberculosis . However, the role of MSMEG-2392 and Rv2983 
in F 420biosynthesis has remained unexplored.
Loss-of-function mutations in ddn,fgd1 and fbiA-C causing delamanid and pretomanid resistance
are readily selected in vitro in M. tuberculosis complex ( 16, 18, 21-23 ). However, the genetic 
spectrum of mutations emerging during in vivo selection has not been characterized. In order to 
study bacterial genetic, host and pharmacological factors associ ated with emergence of 
nitroimidazole resistance in vivo , we selected pretomanid-resistant mutants using a wide range 
of pretomanid doses in two mouse models of TB and characterized them by whole genome 
sequencing (WGS). Because the lungs of TB patients feature a hete rogeneous array of lesion 
types associated with diversified immune responses and drug penet ration ( 24, 25 ), we used both 
C3HeB/FeJ mice, which develop caseating lung lesions in respons e to M. tuberculosis infection, 
and BALB/c mice, which do not, to investigate the impact of these  caseating lesions and their 
associated micro-environments on mutant selection. In the present study, we found that 
pretomanid-resistant mutants were readily selected by monotherap y in both mouse strains. While 
the majority of resistant isolates harbored isolated mutations in  genes previously associated with certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 5 
 nitroimidazole resistance, all the resistant isolates lacking such  mutations had mutations in 
Rv2983 . We went on to confirm that loss-of-function mutations in Rv2983 cause high-level 
pretomanid and delamanid resistance through disruption of F 420biosynthesis, supporting the 
hypothesis that Rv2983 plays a role similar to cofC in M. tuberculosis . Furthermore, F 420H2-
deficient nitroimidazole-resistant M. tuberculosis mutants, including Rv2983 mutants, were found 
to be hypersensitive to malachite green (MG), an organic compound used as a selective 
decontaminant in solid media for culturing M. tuberculosis , which may have important implications 
for their detection in clinical samples.
MATERIALS AND METHODS
Bacterial strains, media, antimicrobials and reagents. Wild type M. tuberculosis H37Rv 
(ATCC 27294) was mouse-passaged, frozen in aliquots and used in  all the experiments. The wild 
type M. smegmatis strain mc2155 was obtained from the stock in the lab. Unless stated otherw ise, 
Middlebrook 7H9 medium (Difco, BD) supplemented with 10% oleic acid-albumin-dextrose-
catalase (OADC) complex (BD), 0.5% glycerol and 0.05% Tween 80 (Sigma-Aldrich) (7H9 broth)
was used for cultivation. Middlebrook 7H10 agar and selective 7H11  agar (Difco, BD), prepared 
from powder and containing 10% OADC and 0.5% glycerol, were used for comparison of strain
recovery on commercially available agar plates. Lowenstein Jensen  (LJ) slants were purchased
from BD. Pretomanid and delamanid were kindly provided by the Globa l Alliance for TB Drug 
Development (New York, NY).
Mouse infection models and pretomanid treatment. All animal procedures were approved by 
the Animal Care and Use Committee of Johns Hopkins University. A erosol infections were 
performed using the Inhalation Exposure System (Glas-col Inc., Terre Haute, IN), as previously 
described ( 26). Briefly, 6-week-old female BALB/c mice (Charles River, Wilming t o n ,  M A )  a n dcertified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 6 
 C3HeB/FeJ mice (Jackson Laboratories Bar Harbor, ME) were infec ted with a log phase culture 
of M. tuberculosis that was grown in 7H9 broth to O.D.600 nm= 1.0 and then diluted in the same 
medium prior to infection to deliver 50-100 CFU to the lungs. Pret omanid was formulated for oral 
administration as previously described ( 27). Beginning 8 weeks after aerosol infection, mice were 
randomly allocated into groups and treated once daily (5 days per  week) for up to 8 weeks with 
pretomanid at doses of 10, 30, 100, 300 and 1000 mg/kg. Untreated mice were sacrificed on the 
day after aerosol infection and on the day of treatment initiatio n to determine the number of CFU 
implanted in the lungs and pretreatment CFU counts, respectively . Additional mice were sacrificed 
after 3 and 8 weeks of treatment to evaluate the treatment respo nse. Serial 10-fold dilutions of 
lung homogenates were plated on 7H11 agar. Week 8 samples includi ng those from untreated 
mice were also plated in parallel on 7H11 plates containing 0.2 5, 1 and 10 Œºg/ml of pretomanid
to quantify the resistant CFU. Plates were incubated at 37¬∞C for  28 days before final CFU counts 
were determined.
Whole genome sequencing. For each mouse lung that yielded growth on pretomanid-containing
plates, individual colonies and, for a subset of mice, pools of up to 15 colo nies, were randomly
selected from pretomanid-containing plates and sub-cultured in 7H9 brot h prior to extraction of
genomic DNA using the cetyltrimethylammonium bromide (CTAB) pro tocol ( 28) and vortexing
(Genegate, Inc.). 2- »ùJRI genomic DNA was sheared by a nebulizer to generate DNA fragment s. 
The DNA library was prepared using a genomic DNA sample prepara tion kit (Illumina, Inc.), in 
which adapter-ligated DNA fragments were 250-350 bp in length, a nd carried out on an Illumina 
Genome Analyzer II (Illumina, Inc). The sequencer was operated i n paired-end mode to collect 
pairs of reads of 51-bp from opposite ends of each fragment. Ima ge analysis and base-calling 
were done by using the Illumina GA Pipeline software (v0.3). Th e reads that were generated for 
each strain were aligned to the reference genome of M. tuberculosis H37Rv ( 29). Based on 
alignment to the corresponding region in the reference genome, single nucleotide polymorphism certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 7 
 (SNP), insertion and deletion were identified on the genome of resistant strains by using a contig-
building algorithm to construct a local ~200 bp sequence spanni ng the site of mutagenesis ( 30).
Distribution of mutation type and mutation frequency in genes i nvolved in nitroimidazole
resistance was calculated by counting the total number of unique mutations isolated from each
mouse in the same treatment group.
Complementation of an Rv2983 mutation. A 1,044-bp DNA fragment containing the open 
reading frame (ORF) of the wild type Rv2983 gene, including 340 bp of 5‚Äô-flanking sequence and 
59 bp of 3‚Äô-flanking sequence, was PCR-amplified from M. tuberculosis H37Rv genomic DNA 
using primers Rv2983 -1F and Rv2983 -1R (Table S1). The Rv2983 PCR product was ligated into 
XbaI-digested E.coli-mycobacterium shuttle vector pMH94 ( 31) using NE builder HiFi DNA 
assembly kit (NE Biolabs) to generate the recombinant pMH94- Rv2983 vector. Similarly, a 388-
bp DNA fragment containing the hsp60 promoter and a 645-bp DNA fragment of Rv2983 open 
reading frame were amplified from M. tuberculosis H37Rv genomic DNA using primer sets hsp60 -
F and hsp60 -R and Rv2983 -2F and Rv2983 -2R, respectively (Table S1), and ligated into XbaI-
digested E.coli-mycobacterium shuttle vector pMH94 to yield pMH94- hsp60 -Rv2983 .A  s m a l l  
amount of ligation reaction was transferred into E. coli competent cells, followed by DNA 
sequencing of the inserts in the corresponding recombinants. The  recombinants pMH94- Rv2983 
and pMH94- hsp60 -Rv2983 were electroporated into competent cells of Rv2983 mutant strain
BA_101 (B101), harboring an A198P substitution, to enable selection of complemented
candidates B101p Rv2983 and B101p hsp60-Rv2983 o n  7 H 1 0  a g a r  c o n t a i n i n g  2 5  Œº g / m l  o f  
kanamycin. To confirm the complementation genetically, Southern b lotting was performed using 
a digoxigenin (DIG) DNA labeling and detection kit according to t he manufacturer‚Äôs protocol 
(Sigma). Briefly, a 448-bp Rv2983 probe was generated by addition of DIG-dUTP (Sigma) to PCR 
reactions containing primer pairs Rv2983 -3F and Rv2983 -3R (Table S1). Acc65I-digested (NE 
biolabs) genomic DNA of the wild type, the B101 mutant and the B10 1pRv2983 and B101p hsp60-certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 8 
 Rv2983 complemented strains was separated on agarose gel and transferre d onto positively-
charged nylon-membrane (GE). After pre-hybridization, the membra ne was hybridized with the 
DIG-labeled Rv2983 probe at 68¬∞C overnight, followed by addition of anti-DIG alkaline  
phosphatase conjugate. After stringent washes, the membrane was incubated wi th the 
chemiluminescence substrate disodium 3-(4-methoxyspiro {1,2-dio xetane-∆ç-
chloro)tricycloecan}-4-yl)phenyl phosphate (CSPD) and exposed on X-ra y  fi l m i n a  da r k roo m  
prior to development using a developer (AFP imaging)( 32).
MIC determination. Log-phase cultures were diluted to achieve a bacterial density of  
approximately 105CFU/ml in conical tubes containing 7H9 broth without Tween 80. Ser ial 10-fold 
dilutions were plated on 7H11 agar containing stepwise 2-fold incre asing pretomanid
concentrations ranging from 0.015 to 64 Œºg/ml or delamanid concentra tions from 0.001 to 1.024
Œºg/ml. Drugs were initially dissolved in dimethylsulfoxide (DMSO ) (Sigma) prior to further dilution 
in 7H9 broth or 7H11 agar. Cultures were incubated at 37¬∞C for 14  days or 28 days after plating.
MIC was defined as the lowest drug concentration that inhibited visible M. tuberculosis growth in 
conical tubes or that inhibited 99% of CFU growth on pretomanid-c ontaining plates ( 33, 34 ). The 
experiments were repeated twice.
Construction of recombinants overexpressing Rv2983 , with or without fbiC,i n  M. 
smegmatis .A 645-bp DNA fragment containing the Rv2983 ORF was PCR-amplified from M. 
tuberculosis H37Rv genomic DNA using primers Rv2983 -4F and Rv2983 -4R (Table S1). The 
amplified PCR product was ligated into the NdeI- and PacI-digeste d E.coli-mycobacterium
shuttle vector pYUBDuet ( 35) using NE builder HiFi DNA assembly kit (NE Biolabs) and then
transferred into Turbo-competent E. coli cells (NE Biolabs) prior to plating on LB agar plates 
containing 100 Œºg/ml of hygromycin B for selection of recombinants .The Rv2983 PCR product 
was also similarly ligated into the same NdeI- and PacI-digested  pYUBDuet vector harboring certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 9 
 fbiC(termed p fbiC)(35) to overexpress both Rv2983 andfbiC. After confirmation by restriction 
digestion and DNA sequencing, the constructs were electroporated into competent M. 
smegmatis cells prior to selecting recombinants on 7H10 agar plates contain ing 100 Œºg/ml of 
hygromycin B. PCR amplification wa s used to confirm the inserts on the M. smegmatis genome.
pYUBDuet and pYUBDuet harboring fbiA, fbiB and fbiC (termed p fbiABC)( 35)w e r ea l s o
transferred into competent M. smegmatis cells to serve as controls.
Measurement of Fo and F 420.Extraction of Fo and F 420was performed in M. smegmatis andM. 
tuberculosis strains according to a previous study ( 35), with minor modifications. Briefly, M. 
smegmatis strains harboring different constructs and pYUBDuet were grown i n 7H9 broth in a 
shaker to mid-log phase (O.D. 600nm = 0.7-1.0), followed by induction using 1mM i VRSURS\O»ï -D-1-
thiogalactopyranoside (IPTG) for 6 and 26 hours. After centrifugat ion for 15 min at 16000 x g, the 
supernatants were removed for detection of Fo, which is principally found in culture supernatant 
whereas F 420 with 5 or 6 glutamate residues is largely retained inside cells ( 15, 35, 36 ). The cell 
pellets were washed with 25mM sodium phosphate buffer (pH 7.0) a nd re-suspended at 100
mg/mL in the same buffer, then autoclaved at 121¬∞C for 15 min. Afte r centrifugation at 16000 x g
for 15 min at 4¬∞C, the cell extracts were harvested for detection of F 420(35). Fluorescence of the 
supernatant and cell extracts was measured using an excitation wa velength of 410 nm and an 
emission wavelength of 465 nm. Fluorescent signals of Fo were nor malized using the O.D. at 
600nm. The small portion of Fo (1-7%) retained inside cells was ig nored when quantifying F 420in 
cell extracts ( 37). Relative fluorescent signals were calculated in M. smegmatis harboring each of 
recombinants relative to pYUBDuet alone. Similarly, cell extracts  and supernatant were extracted 
from M. tuberculosis strains grown in 7H9 broth for 6 days at initial O.D. 600nm of 0.1. Relative 
fluorescent signals of F 420 and Fo were calculated using cell extracts and supernatant relat ive to 
25 mM phosphate buffer and 7H9 broth, respectively. M. smegmatis harboring pYUBDuet- fbiABC certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 10 
 was used as a positive signal control for Fo and F 420due to their commercial unavailability ( 35).
The experiment was repeated twice.
Quantification of gene expression in M. tuberculosis .6-day-old M. tuberculosis strains grown 
in 7H9 broth as described above were sub-cultured in fresh 7H9 at  O.D. 600nm = 0.05 followed by 
incubation at 37 ¬∞C in a shaker for 2 and 4 days. Bacterial pellets were collected by centrifugation 
at 3500 rpm at 4¬∞C for purification of total RNA using Trizol ( Thermo Fisher Scientific) according 
to the manufacturer‚Äôs protocol followed by removal of DNA conta mination with Turbo DNAse 
(Ambion). Following cDNA synthesis with random hexamers and olig o(dT)20 primer and 
superscript III reverse transcriptase (Invitrogen), quantitativ e PCR was performed to measure
gene expression of M. tuberculosis using  SYBR Green PCR master mix (Thermo scientific) and 
StepOneTM system (Applied biosystems) with primer sets listed in Table S1. T he cycle threshold 
value (C T) measured for each gene was normalized to that of the housekeep ing gene sigA ¬®& T)
amplified by the primers sigA-F and sigA-R (Table S1). ¬®¬®& Twas calculated in each of 
pretomanid-resistant strains relative to the wild-type H37Rv prior to calculation of the fold-change 
in gene expression (2^- ¬®¬®& T)(38). All samples were prepared in duplicate. PCR was performed 
from an equal amount of cDNA samples synthesized with oligo(dT)2 0 with primers fbiC-5-7_F
andfbiC-5-7_R (Table S1) using the Q 5High-fidelity PCR kit (New England Biolabs) and C1000 
Thermal cycler (Biorad). The PCR product was examined by electro phoresis on a 1% agarose 
gel.
Malachite green susceptibility testing. 7H9 media supplemented with 10% OADC, 0.5% 
glycerol, 1.5% BactoTM Agar (BD) and malachite green (MG) oxalate (Alfa Aesar) was used to 
prepare solid 7H9 media with differing MG concentrations. M. tuberculosis strains were grown to 
mid-log phase and diluted to OD 600nm = 0.1 in 7H9 broth before serial 10-fold dilutions were plated 
in 100 or 500 Œºl aliquots on 7H9 agar containing MG concentration s of 0, 0.1, 0.3, 1, 3, 10, 30, certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 11 
 100, 300, 1000 Œºg/ml or 0, 3, 6, 12 Œºg/ml. CFU were counted after 28, 35 and 49 days of 
incubation. The same cultures were also plated on 7H10 and 7H11 agar plates and LJ slants.
Serially diluted cultures were inoculated onto LJ slants using cal ibrated disposable inoculating 
loops (10 Œºl per loop, BD) as one l oop per LJ slant. Plates were incubated at 37¬∞C for 21, 28 and 
35 days for CFU counts. Colony size was observed weekly until day 35, beginning 21 days after 
plating. The experiment was repeated two times under similar condi tions.
Statistical analysis. Log 10-transformed CFU counts, fold-change values of gene expression and  
absorbance (A 410) values of fluorescent signals were used to calculate means and standard 
deviations for each data set. Differences between means were compared by the Student‚Äôs ttest
in Microsoft Excel. Differences in mutation frequencies between t wo mouse models were 
evaluated by Fisher‚Äôs exact test in GraphPad Prism 6. A p-value of < 0.05 was considered 
statistically significant.
RESULTS
Spontaneous pretomanid-resistant mutants exist at a relatively h igh frequency in 
infected mice and are selectively amplified by treatment with ac tive doses of pretomanid.
To study the dose-response of pretomanid and explore the genetic s pectrum of nitroimidazole 
resistance selected in vivo , we established chronic M. tuberculosis infections in BALB/c and 
C3HeB/FeJ mice and then treated with a range of pretomanid doses f or up to 8 weeks. Despite 
lower CFU counts on the day after infection (W-8) in C3HeB/FeJ mice  (1.67 log 10CFU per lung) 
compared to BALB/c (2.26 log 10) (p<0.001), higher CFU counts were observed in C3HeB/FeJ 
mice 8 weeks later on the day treatment started (D0) and after 3 weeks of treatment in almost all 
groups ( p<0.001 - 0.05) (Fig. 1A). Three C3HeB/FeJ mice treated with 1000 mg /kg required 
euthanasia during the second week of treatment, prompting a dose  reduction from 1000 mg/kg to 
600 mg/kg in both strains. Nevertheless, a clear pretomanid dose -response relationship was certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 12 
 observed in both mouse strains after 3 weeks of treatment (Fig. 1 A). The three remaining 
C3HeB/FeJ mice treated with 600 mg/kg beyond the week 3 time po int were euthanized after 5 
ZHHNVRIWUHDWPHQWGXHWRWR[LFLW\2QHKDGQRGHWHFWDEOH&)8D QGWZRKDG¬îORJ 10CFU of 
pretomanid-resistant M. tuberculosis . After 8 weeks of treatment, total CFU counts fell in a dose-
dependent manner in BALB/c PLFHEHIRUHDSODWHDXZDVUHDFKHGDWGRVHV¬ïPJNJZKHUH
resistant CFU were higher and replaced the susceptible CFU ( p< 0.05) (Fig. 1B). Spontaneous 
pretomanid-resistant CFU comprised approximately 10-5of the total CFU in the absence of drug 
pressure in untreated BALB/c mice and the proportion of the tot al CFU that was comprised of 
pretomanid-resistant CFU increased with dose up to the 300 mg/k g dose group. Dose-dependent 
bactericidal activity was also observed in C3HeB/FeJ mice (Fig. 1C). However, selective 
amplification of pretomanid-resistant mutants was more extensive and occurred at lower doses 
than in BALB/c mice (Fig. 1B and 1C). We were not able to measure  the spontaneous frequency 
of resistant mutants in untreated C3HeB/FeJ mice because they su ccumbed to infection prior to 
week 8. Pretomanid-resistant CFU replaced susceptible CFU in C3 HeB/FeJ mice receiving doses 
as low as 30 mg/kg and pretomanid-resistant CFU counts were rou ghly 10 times higher in 
C3HeB/FeJ mice compared to BALB/c mice (Fig. 1B and C), which in dicates greater potential for 
selective amplification of pretomanid resistance with monothera py in this strain. Most resistant 
isolates grew on plates containing 10 Œºg/ml of pretomanid, but some had fewer CFU on plates 
containing 10 Œºg/ml than on those containing 1 Œºg/ml of pretoman id.
Whole genome sequencing of pretomanid-resistant mutants revealed  diverse mutations in 
Rv2983 or in one of five other genes required for pretomanid activation.
To characterize mutations associated with pretomanid resistance in vivo , we performed WGS on 
136 individual pretomanid-resistant colonies and 25 colony pools picked from 47 individual mice
harboring pretomanid-resistant CFU after 8 weeks of treatment (Ta ble S2 and S3). Each 
individual isolate had an isolated mutation in Rv2983 or one of the 5 genes previously shown to certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 13 
 be required for pretomanid activation. Overall, 99 unique mutati ons in these 6 genes were 
identified from individual and pooled isolates (Table 1 and 2). E xcept for mutations K9N ( fgd1), 
R322L ( fbiC) and Q120P ( fbiA), which were shared by two mice each, no two mice harbored the 
same mutation, which emphasizes the large target size for resist ance-conferring mutations. In
both BALB/c and C3HeB/FeJ mice, more than half of the resistant isolates were fbiCmutants (54 
and 56%, respectively) (Table 3). For the other five genes, the ran k order by mutation frequency 
was Rv2983 (15%) > fbiA(13%) > ddn(9%) > fbiB(6%) > fgd1 (4%) in BALB/c mice and fbiA
(18%) > ddn (16%) > fgd1 orRv2983 (4%) > fbiB (2%) in C3HeB/FeJ mice. No significant 
differences in mutation frequencies between BALB/c and C3HeB/FeJ m ice were observed, 
although a trend towards more Rv2983 mutations in BALB/c mice (8/54, 15% of all mutations)
compared to C3HeB/FeJ mice (2/45, 4%) was detected. The mutations i dentified in Rv2983
included 8 point mutations resulting in the following amino acid  substitutions: R25S, R25G, A68E,
A132V, G147C, C152R, Q114R and A198P , as well as an insertion of C  after A27 and a deletion 
of I129 (-ATC) (Tables 1 and 2). The overall frequency distribution of unique mutations was as 
follows: fbiC (55%, n= 54), fbiA(15%, n = 15), ddn (12%, n = 12), Rv2983 (10%, n=10), fgd1 (4%, 
n= 4), and fbiB (4%, n=4) (Fig. 2 and Table S4). There were no clear associations  between 
pretomanid dose and the mutated gene. Mutations in fbiCcomprised a higher proportion of those 
selected in our in vivo study compared to the proportion selected in a previous in vitro study (26%, 
p= 0.0001)( 22). On the other hand, mutations in ddn(29%) were more frequent after in vitro
selection than in our mouse models (12%) ( p=0.001). In vitro mutation frequencies for fbiA,fgd1
andfbiB(19%, 7% and 2%, respectively) were similar to our findings in m ice.
Among the 99 unique mutations, all but one (an IS6110 insertion loc ated in 85-bp upstream of 
the fbiCcoding sequence in isolate KA-026a (Table 2 and Table S2) were found within the coding 
regions of the six genes. In total, 54% (53/99) were non-synonymou s point mutations (no 
synonymous point mutations were identified), 35% (35/99) were insertions or deletions (indels),certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 14 
 and 11% (11/99) were substitutions resulting in a stop codon. No sig nificant difference in the
distribution of point mutation and indels was found between our s and the in vitro study by Haver, 
et al, in which non-synonymous point mutations and indels were 50% (7 5/151) and 24% (36/151),
respectively. However, the frequency of stop codon substitutions in the latter study (26%, 40/151) 
was higher than that observed in the present study (11%, 11/99) ( p= 0.004), 85% (34/40) of which 
were in ddnin the latter study ( 22). Non-synonymous point mutations predominated relative to 
indels and stop codon mutations overall and in each gene except  for ddn(Fig. 2 and Table S4). 
The frequency of point mutations was similar between BALB/c and C 3HeB/FeJ mice (56% versus 
51%) (Table 3). A higher frequency of indels occurred in C3HeB/FeJ compared to BALB/c mice 
(44% versus 28%), while more stop codon mutations occurred in BALB/ c, but these differences 
were not statistically significant. There was no clear associati on between dose of pretomanid and 
the type of mutation selected.
Comparing the 99 unique mutations identified in our study with th e 151 unique mutations in 5 of 
the same genes selected in vitro (22), only 4 mutations were found in the same position. Only
W79 stop ( fbiA) and N336K ( fbiC) mutations were found in both datasets while both T273 and 
H190 ( fbiC) were mutated in the same position but with different mutations. As expected from the 
fact that most mutants could be isolated on plates containing 1 0 Œºg/ml of pretomanid, MICs 
determined against a small subset of isolates indicated high-level pretomanid resistance (Table 
S5 and Table 1 and 2). Taken together, these data illustrate the tremendous diversity of mutations
capable of conferring high-level pretomanid resistance.
Mutations in Rv2983 cause resistance to pretomanid and delamanid.
To prove that mutations in Rv2983 are sufficient for nitroimidazole resistance, merodiploid 
complemented strains were constructed by introducing a copy of t he wild type Rv2983 gene into 
B101, an Rv2983 mutant (A198P), through site-specific integration ( 31, 32 ). Following certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 15 
 confirmation of successful integration by Southern blot using a DIG-labeled Rv2983 probe (Figs.
S1A and S1B), susceptibility testing by 7H9 broth dilution confirmed  significantly higher 
nitroimidazole MICs against the Rv2983 mutant (pretomanid and delamanid MICs of 32 Œºg/ml 
and 0.064-0.128 Œºg/ml, respectively) and full restoration of susceptibility in the complemented 
strains (pretomanid and delamanid MICs of 0.25 Œºg/ml and 0.008 Œºg/m l, respectively).
Rv2983 is required for F 420biosynthesis.
To demonstrate that Rv2983 is required for F 420biosynthesis, we measured the production of Fo
and F 420inM. smegmatis strains overexpressing Rv2983 and in M. tuberculosis Rv2983 mutant
strains compared with their corresponding control strains. Rv2983 andfbiC were successfully 
cloned into pYUBDuet and p fbiC(designated p Rv2983 and pfbiC -Rv2983 , respectively), followed 
by successful transformation of M. smegmatis , along with pYUBDuet and p fbiABC , which were 
confirmed by restriction enzyme digestion, DNA sequencing and P CR amplification (data not 
shown). Overexpression of Rv2983 in M. smegmatis increased F 420production but resulted in 
little change in Fo production compared to the control strain after 6 and 26 hours of induction with 
IPTG (Figs. 3A and 3B). As expected, mutation of Rv2983 in the M. tuberculosis B101 mutant 
markedly reduced F 420production, resulting in accumulation of Fo. Complementation ful ly 
restored the wild-type phenotype (Figs. 3C and 3D). In order to evaluate the method, we also 
overexpressed fbiC, which encodes the Fo synthase, with and without concomitant 
overexpression of Rv2983 in M. smegmatis . As expected, overexpression of fbiC increased Fo 
and, consequently, F 420concentrations. Relative to the control strain, F 420concentrations were
similar when either fbiC orRv2983 was over-expressed alone (Fig. 3A). Interestingly, when 
Rv2983 was co-overexpressed with fbiC, a dramatic increase in F 420was observed relative to 
over-expression of either gene alone (3.4 and 3.1-fold, respectiv ely) after 6 hours of IPTG 
induction ( p<0.001), with corresponding significant decreases of Fo levels afte r 6 and 26 hours of 
IPTG induction (5.8 and 3.1-fold; p<0.005 and 0.05, respectively) (Fig. 3A and 3B). These resultscertified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 16 
 suggest that the excess Fo produced by fbiC over-expression was efficiently converted to F 420by 
over-expressed Rv2983. On the other hand, although a small amount of F 420 was observed in cell 
extracts of two Rv2983 point mutants (B101 [A198P] and KA016 [Q114R]), their F 420content was
significantly lower than that of the wild type (7.3 and 7.7-fold )(p< 0.001) and complemented B101 
mutant (Fig. 3C). As expected, Fo accumulated in the two Rv2983 mutant strains relative the wild-
type (6.7 and 6.5-fold; p<0.05 and 0.005, respectively) (Fig. 3D), indicating that Fo was not 
efficiently converted to F 420 in the presence of a mutated Rv2983 . Two other pretomanid-resistant 
strains were also assessed as controls. The KA026 mutant with an IS6110 insertion 85 bp 
upstream of fbiChad undetectable Fo and very little F 420content, while the KA91 mutant with an
IS6110 insertion at amino acid position 108 of Ddn showed a wild-type phenotype with respect to
F420 and Fo concentrations (Fig.3C and D). 
To understand the effect of mutations on gene expression and it s regulation, we performed RT-
qPCR after sub-culturing the M. tuberculosis strains in fresh 7H9 broth. Expression of Rv2983
andfbiCincreased 2.4- and 1.6-fold, respectively, in the Rv2983 mutant B101 relative to the wild-
type H37Rv parent after 4 days of incubation in 7H9 broth. Simila r increases were observed in
other genes such as fbiA (2.3-fold), fbiB(2.0-fold) and fgd1 (2.2-fold) involved in F 420biosynthesis, 
suggesting that the reduced F 420content caused by the Rv2983 A198P mutation resulted in 
upregulation of the F 420biosynthesis pathway (Fig. S2A). Expression of fbiC in the KA026 mutant  
decreased 114-fold compared to that in the wild-type H37Rv parent after 2 days of incubation in 
7H9 broth, likely resulting from interrupted fbiCtranscription as a result of the insertion IS6110 at 
85-bp upstream and explaining the low levels of both Fo and F 420in that mutant (Fig. S2 B). A
faint band representing the fbiC DNA fragment of 937-bp from the fbiCKA026 mutant relative to 
H37Rv further supports this conclusion (Fig. S2C).
F420-deficient pretomanid-resistant mutants are attenuated for grow th in the presence of 
malachite green.certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 17 
 Previous work using M. smegmatis showed that mutations in MSMEG_5126 (homolog of fbiC)
and MSMEG_2392 (which shares 69% homology with Rv2983 ) reduce the ability to decolorize
and detoxify MG, indicating that F 420is necessary for this process ( 20). To evaluate the role of 
each gene associated with nitroimidazole activation in the susce ptibility to MG, log-phase cultures 
of 10 selected mutants were plated on 7H9 agar supplemented with a range of MG
concentrations. All mutants deficient in F 420synthesis or reduction ( i.e., those with mutations in 
fbiA-C ,Rv2983 or fgd1) were more susceptible to MG, while the ddnmutant retained the same 
susceptibility as the wild type H37Rv parent, whose growth was al most completely inhibited at
0*FRQFHQWUDWLRQV¬ï¬óJPO (Fig. 4A). The lability of F 420H2and lack of a commercial source for 
F420made it unfeasible to attempt to test whether provision of F 420H2could rescue the MG-
hypersusceptible phenotype of the F 420H2-deficient mutants. To confirm that Rv2983 is necessary 
for the intrinsic resistance of M. tuberculosis to MG, we compared the growth of the B101 mutant 
to that of the wild type and complemented strains on MG. Again, grow th of this Rv2983 mutant 
was inhibited by lower concentrations of MG than the wild type st rain and required longer 
incubation times before colonies appeared on MG-containing plates (Fig. 4B-D). Plating at higher 
bacterial density (500 Œºl rather than 100 Œºl of cell suspension per plate) significantly increased
recovery (Fig. S3A and B). Complementation of Rv2983 fully restored the wild-type growth 
phenotype on MG concentrations up to 6 Œºg/ml. Interestingly, at MG  concentrations above 6 
Œºg/ml, greater recovery was observed when Rv2983 was expressed behind the native promoter 
compared to the hsp60 promoter (Fig. 4B-D). Smaller colony size was observed in the Rv2983
mutant relative to the wild type and the complemented strains on plates without MG after 21 days 
of incubation but not after 28 days of incubation (Fig. 5). Howeve r, smaller colony size and 
deficient decolorization was observed for the Rv2983 mutant on plates containing MG
concentrations as low as 0.25 and 1 Œºg/ml, even after 28 days of incubation (Fig. 5). At MG
concentrations of 6-12 Œºg/ml, even more-concentrated aliquots of  the B101 mutant culture 
showed markedly reduced recovery despite 42 days of incubation (Fi g. 5).certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 18 
 Because all solid media commonly used to isolate and cultivate M. tuberculosis in clinical 
laboratories contain MG as a selective decontaminant, the increa sed MG susceptibility conferred 
by mutations in fbiA-C,Rv2983 and fgd1 could compromise the isolation and propagation (and 
hence identification) of nitroimidazole-resistant mutants from c linical samples. Commercial 7H10
agar, 7H11 agar and LJ medium contain 0.25, 1 and 400 Œºg/ml, res pectively, of MG. To assess 
the potential impact of these media on the isolation of an F 420H2-deficient nitroimidazole-resistant
Rv2983 mutant relative to an F 420H2-sufficient, but still nitroimidazole-resistant, ddn mutant and 
the nitroimidazole-susceptible wild type and Rv2983- complemented mutant, we inoculated these 
media in parallel using serial dilutions of each strain. The Rv2983 mutant exhibited 10 times lower 
CFU counts and smaller colony size relative to other strains af ter 21 and 28 days of incubation 
on 7H10 agar plates ( p<0.01) (Figs. 6A and C(a)). The result after 35 days of incubat ion was
generally similar between the mutant and the control strains (F ig. 6A and C(b)). A similar semi-
quantitative growth assessment of the Rv2983 mutant on LJ media compared to other strains 
including a ddnmutant (K91, IS6110 ins in D108) revealed growth inhibition of t he Rv2983 mutant 
that was ameliorated by increasing the size of the bacterial in oculum from 102to 106CFU/ml and 
increasing the incubation time from 28 to 35 days (Fig. 6D). In terestingly, no difference in growth 
was found on 7H11 agar (Fig. 6B), even when comparing colony si ze after just 21 days of 
incubation (Fig. 6C(c)), despite higher MG concentrations in th at medium compared to 7H10. 
Unlike 7H10, 7H11 medium contains hydrolysate of casein, which may somehow mitigate against 
the MG toxicity. Taken together, these results indicate that use  of 7H10 and LJ could compromise
the recovery and propagation of F 420H2-deficient nitroimidazole-resistant mutants from clinical 
specimens and that 7H11 agar may be the preferred solid media for processing specimens
propagating any isolates from nitroimidazole-treated patients.certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 19 
 DISCUSSION
As representatives of one of only two new drug classes approved for use against TB in roughly 
50 years, delamanid and pretomani d are important and promising n ew drugs ( 3, 4, 6, 7, 39 ). The 
former received accelerated approval from the EMA for treatment  of MDR-TB and is now used 
clinically, albeit sparingly, while a phase 3 trial is being co mpleted. The latter is being evaluated 
in clinical trials as a component of highly promising regimens for both drug-susceptible and 
MDR/XDR-TB. Comprehensive knowledge of genetic mutations conferring nitroimidazole 
resistance in M. tuberculosis and the resultant mutant phenotypes are critical for timely and 
accurate diagnosis of resistance and, therefore, the safe and effective use of these drugs in the 
clinical setting. Previous work identified 5 genes ( fbiA-C ,fgd1, and ddn) involved in the activation 
pathway of nitroimidazole prodrugs in which mutations may confe r drug resistance in M. 
tuberculosis complex ( 16, 18, 21-23, 40 ). In a prior study of the spectrum of nitroimidazole 
resistance-conferring mutations, Haver, et al found that 151 (83%) of 183 pretomanid-
resistant isolates selected in vitro harbored a single mutation in one of these 5 genes ( 22).
However, 17% of the selected strains harbored no mutations in t hese genes. The present study 
has several important new findings. First, we identified a novel nitroimidazole resistance 
determinant‚Äîmutations in Rv2983 ‚Äîthat explained, in the case of our study, all of the pretomanid 
resistance that was not attributable to mutations in the 5 prev iously described genes. Second, we 
demonstrate for the first time that Rv2983 is required for F 420biosynthesis and likely plays a role 
similar to cofC in the methanogen M. jannaschii (19). Third, we show that Rv2983 and the ability 
to produce F 420H2are essential for full tolerance of M. tuberculosis to the selective decontaminant 
MG, which raises serious concerns about the ability to reliably recover most nitroimidazole-
resistant mutants from clinical samples on the most widely used microbiology media.
Our study provides the first comprehensive analysis of the spec trum of nitroimidazole-resistant 
mutants selected in vivo and, because we used WGS, it represents the most comprehensive certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 20 
 analysis made to-date. Despite the insignificant differences in m utation frequencies between the 
two mouse strains for other genes related to nitroimidazole acti vation, Rv2983 mutations were 
observed with a somewhat higher frequency in BALB/c mice, indica ting a possible host-specific 
fitness cost that warrants further dedicated study. Like the in vitro study by Haver et al (22), we 
found that isolated mutations in fbiA-C ,fgd1, orddnexplained the majority of the pretomanid-
resistant isolates we selected. However, whereas their study le ft 17% of resistant isolates 
unexplained, we found that all of the remaining resistant isolate s, representing 10% of the total 
number of unique mutations, harbored mutations in Rv2983 , a gene not previously implicated in 
nitroimidazole resistance. Indeed, the proportion of resistant isolates explained by Rv2983 (10%) 
was similar to the proportion explained by fbiA (15%) and ddn(12%) mutations, which lagged 
only mutations in fbiC (55%) as the predominant cause of pretomanid resistance in our m ice.
Although the Rv2983 A198T mutation caused a smaller upward shift in the delamanid M IC 
compared to the pretomanid MIC, the delamanid MIC of 0.064-0.12 8 Œºg/ml against the mutant 
was still significantly higher than the recently proposed criti cal concentration of 0.016 Œºg/ml ( 41).
Thus, the identification of Rv2983 mutations should be included in rapid molecular drug 
susceptibility tests and algorithms for the diagnosis of nitroim idazole resistance from genome 
sequence data. The 10 mutations in Rv2983 identified in this study (Table 1 and 2) represent the 
first step in the process of identifying specific resistance-co nferring mutations to inform test 
development.
Rv2983 has 22% amino acid sequence identity to CofC (MJ0887) of M. jannaschii , a putative 
guanylyltransferase involved in the biosynthesis of coenzyme F 420from the precursor Fo. CofC is 
believed to catalyze the condensation of 2-phospho-L-lactate (LP )  a n d  G T P  t o  f o r m  l a c t y l - 2 -
diphospho-5‚Äô-guanosine (LPPG) and PP i(19). Subsequent condensation of LPPG with Fo
catalyzed by CofD (FbiA) forms F 420‚Äì0 and is followed by sequential addition of glutamate
residues by CofE (FbiB) to produce F 420with a poly-glutamate tail ( 19). Up to now, a CofC homolog certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 21 
 has not been identified in M. tuberculosis . It is known that Fo biosynthesis is catalyzed by FbiC,
but it is not clear how Fo is modified by FbiA to form F 420‚Äì0. Bashiri, et al tried to understand the 
mechanism by overexpressing fbiC in the saprophyte M. smegmatis , which did not dramatically 
increase F 420biosynthesis, suggesting that an additional intermediate is req uired to form F 420‚Äì0
from Fo ( 35). Using overexpression of Rv2983 in M. smegmatis and M. tuberculosis Rv2983 
mutants, we provide initial evidence that Rv2983 catalyzes an important step required for 
synthesis of F 420from Fo in the pathogen M. tuberculosis , which adds to previous evidence that
its ortholog MSMEG_2392 is involved in F 420biosynthesis in M. smegmatis (20). The validity of 
the method used in this study for detection of F 420and Fo was demonstrated by showing the 
expected results with two pretomanid-resistant strains, KA016 and KA026, harboring mutations 
infbiC andddn, respectively. Although the role of Rv2983 remains to be confirmed, our results 
confirm that expression of Rv2983 is necessary for efficient conversion of Fo to F 420(Fig. 3G).
Our results confirm and significantly extend prior in vitro work demonstrating the remarkable 
diversity of mutations capable of conferring high-level nitroim idazole resistance. Among the 99
unique mutations we identified in 47 mice, only 3 mutations (K9N in  fgd1, R322L in fbiC and
Q120P in fbiA) were found in more than one mouse. Furthermore, by comparing t he 99 unique 
mutations observed in our mice with the 151 unique mutations sele cted in vitro (22), the same 
mutation occurred only twice. Thus, each of the 6 genes now impli cated in nitroimidazole 
resistance appears to be devoid of ‚Äúhot spots‚Äù for such mutations.  The frequency of spontaneous
mutations conferring nitroimidazole resistance in M. tuberculosis has been investigated in vitro by 
several studies and found to range from 1 in 105to 7 in 107CFU ( 21-23, 27, 40, 42 ), which is 
consistent with our findings in the lungs of untreated BALB/c mi ce. The large ‚Äútarget size‚Äù for 
mutations in 6 non-essential genes drives these high frequencies o f spontaneous nitroimidazole-
resistant mutants in M. tuberculosis populations, which is as high or higher than that for isoniazid 
and other TB drugs in clinical use. Our unpublished observations s uggest that similar frequencies certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 22 
 of nitroimidazole-resistant mutants exist in sputum isolates co llected from treatment-na√Øve, drug-
susceptible TB patients. Delamanid-resistant M. tuberculosis has been recovered from patients 
both before and after delamanid treatment ( 10, 43-45 ). To date, emergence of resistance has not 
been described during use of pretomanid in clinical trials, but s uch use has been restricted to 
relatively short treatment durations and/or use of highly activ e companion drugs. Pretomanid 
resistance has emerged during combination therapy in mouse model s(3, 46 ). Thus, the relatively 
high frequency of spontaneous mutations conferring nitroimidazole resistance and available pre-
clinical and clinical data underscore the importance of making validated drug susceptibility testing 
for this class widely available as clinical usage expands. The u nprecedented number and diversity 
of resistance-conferring mutations demonstrated for nitroimidaz ole drugs here and by Haver et al
(22), clearly challenges the development and interpretation of rapi d molecular susceptibility tests,
especially considering that polymorphisms in nitroimidazole res istance genes that represent 
phylogenetic markers but do not confer pretomanid resistance are w ell-described ( 47, 48 ). A
similar situation exists for pncA mutations and pyrazinamide (PZA) resistance, where an efficient, 
yet comprehensive method based on saturating mutagenesis for dis tinguishing single nucleotide 
polymorphisms conferring resistance was recently described ( 49). A similar analysis of 
substitutions in the 6 genes related to nitroimidazole resistance would similarly advance the 
development of drug susceptibility testing using genome sequencin g technology. 
Amino acid substitutions in the PZA-activating PncA protein tha t confer PZA resistance are 
associated with diminished enzymatic activity or reduced abundan ce of the protein (49 ). Similar 
mechanisms could explain the overall mechanisms of the 99 mutatio ns we identified in the six 
genes conferring nitroimidazole resistance. The Rv2983 A198P or Q114R substitutions may 
change the conformation of Rv2983 protein structure and reduce its enzymatic activity given that 
it has no effect on Rv2983 gene transcription. F 420biosynthesis is dramatically decreased while 
expression of Rv2983 and other genes increases, perhaps indicating an unknown regulator y certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 23 
 mechanism triggered by reduced F 420biosynthesis. Mutations identified in Rv2983 in this study 
will provide useful information for future studies on structure -function associations of the potential 
M. tuberculosis CofC homolog. The KA026 mutant harboring an IS6110 insertion 85 b p upstream 
offbiC exhibited significantly decreased expression of fbiC, possibly due to interruption of the 
promoter region, and, consequently, almost complete loss of Fo syn thase activity. Hence, the 
upstream regulatory regions of the six genes also should be con sidered in future identification of 
resistance-conferring mutations, although their prevalence in th is study was only 1%.
Our findings regarding the heightened susceptibility of F 420H2-deficient mutants to MG pose a 
previously unappreciated challenge to the development and use o f phenotypic testing methods. 
Indeed, we observed reduced or delayed recovery of a nitroimidaz ole-resistant Rv2983 mutant 
on commercial 7H10 and LJ media that include MG as a selective decontaminant ( 50). Since fbiA-
Candfgd1 mutants, as well as a second Rv2983 mutant, exhibited similar hypersusceptibility to 
MG in 7H9 agar supplemented with MG, their recovery on 7H10 and L J is also likely to be affected.
Selective growth inhibition of nitroimidazole-resistant strains  on media that are commonly used in 
clinical microbiology laboratories around the world raises seri ous concern that their recovery from 
clinical specimens may be impaired to such an extent that it reduc es the sensitivity and accuracy 
of phenotypic drug susceptibility testing, especially for isola tes comprised of mixed wild-type and 
resistant populations. This concern is further amplified by the common practice of performing 
susceptibility testing (including molecular testing), not on pr imary samples but, on isolates that 
have been sub-cultured one or more times on solid media. Such p ractices may drastically reduce 
the proportion of (or eradicate) F 420H2-deficient mutants present in the original sample. In addition, 
efforts to develop MG decolorization assays for detection of dr ug-resistant TB are expected to be 
fruitless for these mutants ( 51-54 ). We did not determine the basis for the greater recovery of 
F420H2-deficient mutants on 7H11 vs. 7H10 media despite 4x higher tot al MG concentrations in 
the former. The principal differences between these media are t he presence of pancreatic digest certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 24 
 of casein in 7H11 and lower concentrations of magnesium sulfate countered by the addition of 
copper sulfate, zinc sulfate and calcium chloride in 7H10. Alth ough this issue clearly requires 
further study, we presently believe that 7H10 and LJ should not be employed for phenotypic 
nitroimidazole susceptibility testing and that primary isolation  or subculture of any isolate on such 
media prior to either phenotypic or genotypic susceptibility te sting should be avoided whenever 
possible. When it cannot be avoided, larger inoculum sizes and l onger incubation times may 
increase recovery on 7H10 and LJ. Based on our study, 7H11 agar  appears to be the preferred 
solid medium for recovery of F 420H2-deficient nitroimidazole-resistant M. tuberculosis .
A role for cofactor F 420H2in tolerance of was previously demonstrated ( 20). Whereas 
mycobacteria are normally capable of decolorizing and detoxifyi ng MG, mutations in the 
saprophyte M. smegmatis orthologs of fgd1,fbiC andRv2983 disrupt this ability and/or reduce 
the MIC of MG ( 20, 55 ). We now extend these observations to the pathogen M. tuberculosis and 
also implicate fbiA andfbiB, but not ddn, in MG tolerance. In Citrobacter species, an NADH-
dependent triphenylmethane reductase catalyzes reduction of MG to colorless leucoMG that lacks 
antimicrobial activity and is sequestered in the lipid fraction  of the cells ( 56, 57 ). Triphenylmethane 
reductase has not been identified in mycobacteria. However, the enhanced MG susceptibility of 
the F 420H2-deficient mutants, but not ddnmutants, suggests that one or more analogous, yet 
unidentified, F 420H2-dependent reductases is responsible for decolorizing and detox ifying MG in 
mycobacteria. 
Prior studies indicated other fitness costs associated with F 420H2deficiency, such as 
hypersusceptibility to oxidative and nitrosative stresses ( 12, 58, 59 ). Nevertheless, we observed 
selective amplification of F 420H2-deficient mutants in mice over a range of pretomanid doses tha t 
included doses producing much higher drug exposures than those p roduced in patients. 
Amplification was especially pronounced at higher drug doses, w hich eliminated the majority of 
nitroimidazole-susceptible population more effectively, and in C3HeB/FeJ mice. The lack of certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 25 
 marked in vivo fitness defects is also supported by the fact that the proportio n of all unique 
resistance mutations explained by each mutation did not differ much between the in vitro and in 
vivo conditions, except that a higher proportion of fbiCmutations predominated in mice, somewhat 
at the expense of ddnmutations ( 22). Likewise, indels and stop codon mutations comprised nearly 
50% of the mutations responsible for resistance. This proportion  may be biased due to the high 
drug doses tested in some mice because such mutations are more likely to result in complete 
loss-of-function and therefore more complete resistance. However , the frequency of such 
mutations did not appear to change in a dose-dependent manner. I nterestingly, most Rv2983 
mutants were selected in BALB/c rather than C3HeB/FeJ mice despi te similar mutation rates in 
other genes between the two mouse strains. Whether this represe nts a real or a random 
difference will require further study. Clearly, clinicians must  rely on effective combination drug 
therapy to prevent the selective amplification of nitroimidazol e-resistant mutants. Heightened 
susceptibility to agents causing oxidative stress has been demo nstrated for F 420H2-deficient M. 
tuberculosis and M. smegmatis mutants ( 58). A more complete understanding of the unique 
vulnerabilities of such mutants should aid in the design of effec tive combination regimens that 
also optimally restrict selection of nitroimidazole-resistant mut ants.
In conclusion, using BALB/c and C3HeB/FeJ mice and WGS, we character ized the pretomanid 
dose-response relationships for bactericidal effect and suppres sion of drug-resistant mutants and 
profiled the genetic spectrum of pretomanid resistance emerging in vivo . A novel resistance 
determinant, Rv2983, was identified as essential for F 420biosynthesis and activation of the novel 
TB pro-drugs delamanid and pretomanid. Furthermore, we provide e vidence that F 420H2-deficient,
nitroimidazole-resistant M. tuberculosis mutants are hypersensitive to MG, raising concern that
using MG-containing medium coul d compromise the isolation and p ropagation of M. tuberculosis
from clinical samples and therefore hinder the clinical diagnos is of nitroimidazole resistance.
These findings have important implications for both genotypic and phenotypic susceptibility certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 26 
 testing to detect nitroimidazole resistance, which will be of in creasing importance as wider use of 
delamanid and, if approved, pretomanid, ensues.
LIST OF SUPPLEMENTARY MATERIALS
Table S1
Table S2
Table S3
Table S4
Table S5
Figure S1
Figure S2
Figure S3
Acknowledgements: The Global Alliance for TB Drug Development kindly provided pre tomanid 
and delamanid. Funding: The authors gratefully acknowledge support in the form of fundi ng from 
the Bill and Melinda Gates Foundation (OPP1037174) (ELN) and the National Institutes of Health 
(R01-AI111992) (ELN). G.B. is supported by a Sir Charles Hercus Fellowship through the Health 
Research Council of New Zealand. Author contributions: D.R. and E.N. conceived the study 
and designed the experiments. S.L. and J.L. assisted with the de sign and conduct of the in vivo 
experiment. Whole genome sequencing was performed and analyzed by T.I., J.S., D.R. and E.N.
In vitro experiments were performed and analyzed by D.R., J.L. and E.N. The manuscript was 
drafted by D.R. and E.N. with critical input from T.I., J.S., a nd G.B. Competing interests: All 
authors declare that they have no competing interests. Data and materials availability: All data 
necessary for evaluation of the conclusions are present in the paper and/or the Supplementary 
Materials. Pretomanid and delamanid were provided under a materi al transfer agreement.certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 27 
 REFERENCES
1. WHO, Global Tuberculosis report. World Health Organization Geneva ,  (2017).
2. WHO, Guidelines for the programmatic management of drug-resis tant tuberculosis. . 
World Health Organization Geneva ,  (2011).
3. S. Y. Li, R. Tasneen, S. Tyagi, H. Soni, P. J. Converse, K. M dluli, E. L. Nuermberger, 
Bactericidal and Sterilizing Activity of a Novel Regimen with B edaquiline, Pretomanid, 
Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosi s.Antimicrobial agents 
and chemotherapy 61,  (2017).
4. R. Tasneen, F. Betoudji, S. Tyagi, S. Y. Li, K. Williams, P. J. Converse, V. Dartois, T. 
Yang, C. M. Mendel, K. E. Mdluli, E. L. Nuermberger, Contributi on of Oxazolidinones to 
the Efficacy of Novel Regimens Containing Bedaquiline and Preto manid in a Mouse 
Model of Tuberculosis. Antimicrobial agents and chemotherapy 60, 270-277 (2015).
5. V. Skripconoka, M. Danilovits, L. Pehme, T. Tomson, G. Skende rs, T. Kummik, A. 
Cirule, V. Leimane, A. Kurve, K. Levina, L. J. Geiter, D. Manis sero, C. D. Wells, 
Delamanid improves outcomes and reduces mortality in multidrug- resistant tuberculosis. 
Eur Respir J 41, 1393-1400 (2013).
6. M. T. Gler, V. Skripconoka, E. Sanchez-Garavito, H. Xiao, J. L. Cabrera-Rivero, D. E. 
Vargas-Vasquez, M. Gao, M. Awad, S. K. Park, T. S. Shim, G. Y. Suh, M. Danilovits, H. 
Ogata, A. Kurve, J. Chang, K. Suzuki, T. Tupasi, W. J. Koh, B. Seaworth, L. J. Geiter, C. 
D. Wells, Delamanid for multidrug-resistant pulmonary tuberculo sis. N Engl J Med 366,
2151-2160 (2012).
7. A. H. Diacon, R. Dawson, F. von Groote-Bidlingmaier, G. Symons, A. Venter, P. R. 
Donald, C. van Niekerk, D. Everitt, H. Winter, P. Becker, C. M. Mendel, M. K. Spigelman, 
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin 
combinations: a randomised trial. Lancet 380, 986-993 (2012).
8. R. Dawson, A. H. Diacon, D. Everitt, C. van Niekerk, P. R. Do nald, D. A. Burger, R. 
Schall, M. Spigelman, A. Conradie, K. Eisenach, A. Venter, P. I ve, L. Page-Shipp, E.
Variava, K. Reither, N. E. Ntinginya, A. Pym, F. von Groote-Bidlingmaier, C. M. Mendel, 
Efficiency and safety of the combination of moxifloxacin, preto manid (PA-824), and 
pyrazinamide during the first 8 weeks of antituberculosis treat ment: a phase 2b, open-
label, partly randomised trial in patients with drug-susceptibl e or drug-resistant 
pulmonary tuberculosis. Lancet 385, 1738-1747 (2015).
9. M. Matsumoto, H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsu bouchi, H. Sasaki, Y. 
Shimokawa, M. Komatsu, OPC-67683, a nitro-dihydro-imidazooxazole derivative with 
promising action against tuberculosis in vitro and in mice. PLoS medicine 3, e466 
(2006).
10. European Medicines Agency, Summary of the European public as sessment report 
(EPAR) for Deltyba. Found at 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Public_assessment_report/human/002552/WC500166234.pdf (2013). Last accessed 
on 18 June 2018.
11. U. Manjunatha, H. I. Boshoff, C. E. Barry, The mechanism of action of PA-824: Novel 
insights from transcriptional profiling. Commun Integr Biol 2, 215-218 (2009).
12. C. Greening, F. H. Ahmed, A. E. Mohamed, B. M. Lee, G. Pande y , A. C. Warden, C. 
Scott, J. G. Oakeshott, M. C. Taylor, C. J. Jackson, Physiology , Biochemistry, and 
Applications of F420- and Fo-Dependent Redox Reactions. Microbiol Mol Biol Rev 80,
451-493 (2016).
13. S. E. Cellitti, J. Shaffer, D. H. Jones, T. Mukherjee, M. Gu rumurthy, B. Bursulaya, H. I. 
Boshoff, I. Choi, A. Nayyar, Y. S. Lee, J. Cherian, P. Niyomrat tanakit, T. Dick, U. H. 
Manjunatha, C. E. Barry, 3rd, G. Spraggon, B. H. Geierstanger, Structure of Ddn, the certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 28 
 deazaflavin-dependent nitroreductase from Mycobacterium tubercu losis involved in 
bioreductive activation of PA-824. Structure 20, 101-112 (2012).
14. G. Bashiri, C. J. Squire, N. J. Moreland, E. N. Baker, Crysta l structures of F420-
dependent glucose-6-phosphate dehydrogenase FGD1 involved in th e activation of the 
anti-tuberculosis drug candidate PA-824 reveal the basis of coe nzyme and substrate 
binding. The Journal of biological chemistry 283, 17531-17541 (2008).
15. D. E. Graham, H. Xu, R. H. White, Identification of the 7,8- didemethyl-8-hydroxy-5-
deazariboflavin synthase required for coenzyme F(420) biosynthe sis. Arch Microbiol
180, 455-464 (2003).
16. K. P. Choi, T. B. Bair, Y. M. Bae, L. Daniels, Use of transp oson Tn5367 mutagenesis 
and a nitroimidazopyran-based selection system to demonstrate a  requirement for fbiA 
and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis  BCG. J Bacteriol
183, 7058-7066 (2001).
17. L. Decamps, B. Philmus, A. Benjdia, R. White, T. P. Begley, O. Berteau, Biosynthesis of 
F0, precursor of the F420 cofactor, requires a unique two radic al-SAM domain enzyme 
and tyrosine as substrate. J Am Chem Soc 134, 18173-18176 (2012).
18. K. P. Choi, N. Kendrick, L. Daniels, Demonstration that fbiC  is required by 
Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis . J Bacteriol 184,
2420-2428 (2002).
19. L. L. Grochowski, H. Xu, R. H. White, Identification and characterization of the 2-
phospho-L-lactate guanylyltransferase involved in coenzyme F420  biosynthesis. 
Biochemistry 47, 3033-3037 (2008).
20. D. Guerra-Lopez, L. Daniels, M. Rawat, Mycobacterium smegmat is mc2 155 fbiC and 
MSMEG_2392 are involved in triphenylmethane dye decolorization and coenzyme F420 
biosynthesis. Microbiology 153, 2724-2732 (2007).
21. C. K. Stover, P. Warrener, D. R. VanDevanter, D. R. Sherman,  T. M. Arain, M. H. 
Langhorne, S. W. Anderson, J. A. Towell, Y. Yuan, D. N. McMurra y, B. N. Kreiswirth, C. 
E. Barry, W. R. Baker, A small-molecule nitroimidazopyran drug candidate for the 
treatment of tuberculosis. Nature 405, 962-966 (2000).
22. H. L. Haver, A. Chua, P. Ghode, S. B. Lakshminarayana, A. Si nghal, B. Mathema, R. 
Wintjens, P. Bifani, Mutations in genes for the F420 biosynthet ic pathway and a 
nitroreductase enzyme are the primary resistance determinants i n spontaneous in vitro-
selected PA-824-resistant mutants of Mycobacterium tuberculosis . Antimicrobial agents 
and chemotherapy 59, 5316-5323 (2015).
23. M. Fujiwara, M. Kawasaki, N. Hariguchi, Y. Liu, M. Matsumoto , Mechanisms of 
resistance to delamanid, a drug for Mycobacterium tuberculosis.  Tuberculosis (Edinb)
108, 186-194 (2018).
24. S. Subbian, L. Tsenova, M. J. Kim, H. C. Wainwright, A. Viss er, N. Bandyopadhyay, J. 
S. Bader, P. C. Karakousis, G. B. Murrmann, L. G. Bekker, D. G.  Russell, G. Kaplan, 
Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary 
Tuberculosis: A Pilot Study. PLoS One 10, e0132249 (2015).
25. D. Rifat, B. Prideaux, R. M. Savic, M. E. Urbanowski, T. L. Parsons, B. Luna, M. A. 
Marzinke, A. A. Ordonez, V. P. DeMarco, S. K. Jain, V. Dartois,  W. R. Bishai, K. E. 
Dooley, Pharmacokinetics of rifapentine and rifampin in a rabbi t model of tuberculosis 
and correlation with clinical trial data. Science translational medicine 10,  (2018).
26. E. L. Nuermberger, T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. 
A. Vernon, R. E. Chaisson, W. R. Bishai, J. H. Grosset, Moxiflo xacin-containing 
regimens of reduced duration produce a stable cure in murine tu berculosis. American 
journal of respiratory and critical care medicine 170, 1131-1134 (2004).certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 29 
 27. S. Tyagi, E. Nuermberger, T. Yoshimatsu, K. Williams, I. Ros enthal, N. Lounis, W. 
Bishai, J. Grosset, Bactericidal activity of the nitroimidazopy ran PA-824 in a murine 
model of tuberculosis. Antimicrobial agents and chemotherapy 49, 2289-2293 (2005).
28. M. H. Larsen, K. Biermann, S. Tandberg, T. Hsu, W. R. Jacobs , Jr., Genetic 
Manipulation of Mycobacterium tuberculosis. Current protocols in microbiology Chapter 
10, Unit 10A 12 (2007).
29. T. R. Ioerger, Y. Feng, K. Ganesula, X. Chen, K. M. Dobos, S . Fortune, W. R. Jacobs, 
Jr., V. Mizrahi, T. Parish, E. Rubin, C. Sassetti, J. C. Sacche ttini, Variation among 
genome sequences of H37Rv strains of Mycobacterium tuberculosis  from multiple 
laboratories. J Bacteriol 192, 3645-3653 (2010).
30. T. R. Ioerger, T. O'Malley, R. Liao, K. M. Guinn, M. J. Hick ey, N. Mohaideen, K. C. 
Murphy, H. I. Boshoff, V. Mizrahi, E. J. Rubin, C. M. Sassetti,  C. E. Barry, 3rd, D. R. 
Sherman, T. Parish, J. C. Sacchettini, Identification of new dr ug targets and resistance 
mechanisms in Mycobacterium tuberculosis. PLoS One 8, e75245 (2013).
31. M. H. Lee, L. Pascopella, W. R. Jacobs, Jr., G. F. Hatfull, Site-specific integration of 
mycobacteriophage L5: integration-proficient vectors for Mycoba cterium smegmatis, 
Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proceedings of the National 
Academy of Sciences of the United States of America 88, 3111-3115 (1991).
32. D. Rifat, D. A. Belchis, P. C. Karakousis, senX3-independent  contribution of regX3 to 
Mycobacterium tuberculosis virulence. BMC microbiology 14, 265 (2014).
33. D. Almeida, T. Ioerger, S. Tyagi, S. Y. Li, K. Mdluli, K. An dries, J. Grosset, J. Sacchettini, 
E. Nuermberger, Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and 
Clofazimine in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy 60,
4590-4599 (2016).
34. Z. Ahmad, C. A. Peloquin, R. P. Singh, H. Derendorf, S. Tyag i, A. Ginsberg, J. H. 
Grosset, E. L. Nuermberger, PA-824 exhibits time-dependent activity in a murine model 
of tuberculosis. Antimicrobial agents and chemotherapy 55, 239-245 (2011).
35. G. Bashiri, A. M. Rehan, D. R. Greenwood, J. M. Dickson, E. N. Baker, Metabolic
engineering of cofactor F420 production in Mycobacterium smegma tis. PLoS One 5,
0015803 (2010).
36. D. Isabelle, D. R. Simpson, L. Daniels, Large-Scale Producti on of Coenzyme F(420)-5,6 
by Using Mycobacterium smegmatis. Applied and environmental microbiology 68, 5750-
5755 (2002).
37. T. B. Bair, D. W. Isabelle, L. Daniels, Structures of coenzy me F(420) in Mycobacterium 
species. Arch Microbiol 176, 37-43 (2001).
38. D. Rifat, P. C. Karakousis, Differential regulation of the t wo-component regulatory 
system senX3-regX3 in Mycobacterium tuberculosis. Microbiology 160, 1125-1133
(2014).
39. R. Dawson, A. H. Diacon, D. Everitt, C. van Niekerk, P. R. D onald, D. A. Burger, R. 
Schall, M. Spigelman, A. Conradie, K. Eisenach, A. Venter, P. I ve, L. Page-Shipp, E. 
Variava, K. Reither, N. E. Ntinginya, A. Pym, F. von Groote-Bid ling maier, C. M. Mendel, 
Efficiency and safety of the combination of moxifloxacin, preto manid (PA-824), and 
pyrazinamide during the first 8 weeks of antituberculosis treat ment: a phase 2b, open-
label, partly randomised trial in patients with drug-susceptibl e or drug-resistant 
pulmonary tuberculosis. Lancet 385, 1738-1747 (2015).
40. U. H. Manjunatha, H. Boshoff, C. S. Dowd, L. Zhang, T. J. Albert, J. E. Norton, L. 
Daniels, T. Dick, S. S. Pang, C. E. Barry, 3rd, Identification o f a nitroimidazo-oxazine-
specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America 103,
431-436 (2006).certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 30 
 41. WHO, Technical report on critical concentrations for TB drug  susceptibility testing of 
medicines used in the treatment of drug-resistant TB. 
http://www.who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug
_susceptibility ,  (2018).
42. J. G. Hurdle, R. B. Lee, N. R. Budha, E. I. Carson, J. Qi, M . S. Scherman, S. H. Cho, M. 
R. McNeil, A. J. Lenaerts, S. G. Franzblau, B. Meibohm, R. E. L ee, A microbiological 
assessment of novel nitrofuranylamides as anti-tuberculosis age nts. J Antimicrob 
Chemother 62, 1037-1045 (2008).
43. G. V. Bloemberg, P. M. Keller, D. Stucki, A. Trauner, S. Bor rell, T. Latshang, M. 
Coscolla, T. Rothe, R. Homke, C. Ritter, J. Feldmann, B. Schult hess, S. Gagneux, E. C. 
Bottger, Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis .
(N Engl J Med. 2015 Nov 12;373(20):1986-8. doi: 10.1056/NEJMc15 05196.).
44. K. Stinson, N. Kurepina, A. Venter, M. Fujiwara, M. Kawasaki , J. Timm, E. Shashkina, B. 
N. Kreiswirth, Y. Liu, M. Matsumoto, L. Geiter, MIC of Delamanid (OPC-67683) against 
Mycobacterium tuberculosis Clinical Isolates and a Proposed Cri tical Concentration. 
Antimicrobial agents and chemotherapy 60, 3316-3322 (2016).
45. H. Hoffmann, T. A. Kohl, S. Hofmann-Thiel, M. Merker, P. Bec kert, K. Jaton, L. 
Nedialkova, E. Sahalchyk, T. Rothe, P. M. Keller, S. Niemann, D elamanid and 
Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype 
Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Re fugee. American 
journal of respiratory and critical care medicine 193, 337-340 (2016).
46. J. Harper, C. Skerry, S. L. Davis, R. Tasneen, M. Weir, I. K ramnik, W. R. Bishai, M. G. 
Pomper, E. L. Nuermberger, S. K. Jain, Mouse model of necrotic tuberculosis 
granulomas develops hypoxic lesions. The Journal of infectious diseases 205, 595-602
(2012).
47. E. Schena, L. Nedialkova, E. Borroni, S. Battaglia, A. M. Ca bibbe, S. Niemann, C. 
Utpatel, M. Merker, A. Trovato, S. Hofmann-Thiel, H. Hoffmann, D. M. Cirillo, Delamanid 
susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay 
and the BACTEC MGIT 960 system. J Antimicrob Chemother 71, 1532-1539 (2016).
48. S. Feuerriegel, C. U. Koser, D. Bau, S. Rusch-Gerdes, D. K. Summers, J. A. Archer, M. 
A. Marti-Renom, S. Niemann, Impact of Fgd1 and ddn diversity in  Mycobacterium 
tuberculosis complex on in vitro susceptibility to PA-824. Antimicrobial agents and 
chemotherapy 55, 5718-5722 (2011).
49. A. N. Yadon, K. Maharaj, J. H. Adamson, Y. P. Lai, J. C. Sac chettini, T. R. Ioerger, E. J. 
Rubin, A. S. Pym, A comprehensive characterization of PncA poly morphisms that confer 
resistance to pyrazinamide. Nature communications 8, 588 (2017).
50. D. V. Cousins, B. R. Francis, B. L. Gow, Advantages of a new  agar medium in the 
primary isolation of Mycobacterium bovis. Veterinary microbiology 20, 89-95 (1989).
51. N. C. Mirabal, S. L. Yzquierdo, D. Lemus, M. Madruga, Y. Mil ian, M. Echemendia, H. 
Takiff, A. Martin, P. Van der Stuyf, J. C. Palomino, E. Montoro , Evaluation of colorimetric 
methods using nicotinamide for rapid detection of pyrazinamide r esistance in 
Mycobacterium tuberculosis. J Clin Microbiol 48, 2729-2733 (2010).
52. A. Y. Coban, M. Uzun, Rapid detection of multidrug-resistant  Mycobacterium 
tuberculosis using the malachite green decolourisation assay. Mem Inst Oswaldo Cruz
108, 1021-1023 (2013).
53. A. Martin, F. Portaels, J. C. Palomino, Colorimetric redox-indicator methods for the rapid 
detection of multidrug resistance in Mycobacterium tuberculosis : a systematic review 
and meta-analysis. J Antimicrob Chemother 59, 175-183 (2007).
54. P. Farnia, F. Mohammadi, M. Mirsaedi, A. Z. Zarife, J. Tabat abee, K. Bahadori, M. 
Bahadori, M. R. Masjedi, A. A. Velayati, Application of oxidati on-reduction assay for certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 31 
 monitoring treatment of patients with pulmonary tuberculosis. J Clin Microbiol 42, 3324-
3325 (2004).
55. T. Jirapanjawat, B. Ney, M. C. Taylor, A. C. Warden, S. Afro ze, R. J. Russell, B. M. Lee, 
C. J. Jackson, J. G. Oakeshott, G. Pandey, C. Greening, The red ox cofactor F420 
protects mycobacteria from diverse antimicrobial compounds and mediates a reductive 
detoxification system. Applied and environmental microbiology ,  (2016).
56. M. S. Jang, Y. M. Lee, C. H. Kim, J. H. Lee, D. W. Kang, S. J. Kim, Y. C. Lee, 
Triphenylmethane reductase from Citrobacter sp. strain KCTC 180 61P: purification, 
characterization, gene cloning, and overexpression of a functio nal protein in Escherichia 
coli. Applied and environmental microbiology 71, 7955-7960 (2005).
57. V. Fessard, T. Godard, S. Huet, A. Mourot, J. M. Poul, Mutagenicity of malachite green 
and leucomalachite green in in vitro tests. J Appl Toxicol 19, 421-430 (1999).
58. M. Gurumurthy, M. Rao, T. Mukherjee, S. P. Rao, H. I. Boshoff, T. Dick, C. E. Barry, 3rd, 
U. H. Manjunatha, A novel F(420) -dependent anti-oxidant mechan ism protects 
Mycobacterium tuberculosis against oxidative stress and bacteri cidal agents. Molecular 
microbiology 87, 744-755 (2013).
59. K. H. Darwin, S. Ehrt, J. C. Gutierrez-Ramos, N. Weich, C. F . Nathan, The proteasome 
of Mycobacterium tuberculosis is required for resistance to nit ric oxide. Science 302,
1963-1966 (2003).
TABLES
Table 1. Mutations identified in 89 individual colonies and poo led isolates of pretomanid-
resistant M. tuberculosis selected in BALB/c mice certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 32 
 Pretomanid No. of
treatment Mouse single isolates Rv3261 (fbiA ) Rv3262 (fbiB ) Rv1173 (fbiC ) Rv3547 (ddn) Rv0407 (fgd1 ) Rv2983 (cofC )
(mg/kg) ID (n=89) 331aa (n=7) 448aa (n=3) 856aa (n=29) 151aa (n=5) 336aa (n=2) 214aa (n=8)
0M - 1 2 -G in aa 38 K9N
M-2 4 R133P (2); -A in aa 503 K9N
M-4 1 W690*
M-5 4 +A in aa 426 (4)
10 M-1 8 A212V L702R (4); C562W -GC in aa 39  +C in aa 27 
M-2 2 9 bp del (aa 307-309);
-TCCCCGATG del in aa 306-308
M-3 4 L15P L772W; -C in aa 252 (2)M-4 5 G147C (5)
M-5 2 A632V  R25G
30 M-1 1 S169P
M-2 3 L211P W20* A132V
M-3 2 R278P (2)
M-4 1 W155*
M-5 3 Q400*; +T in aa 188 (2)
100 M-1 1 -ATC in aa 129
M-2 3 K682E; Y170*; L187RM-3 2 W397R; L173P
M-4 2 F744S -C in aa 93
M-5 4 S219G  M776T (3)
300 M-1 7 R25S (7)
M-2 4 Q27* (3); -G in aa 248M-3 4 H190N; Q20*; -GC in aa 846 (2) 
M-4 4 T707M; T301A; -C in aa 247 9345 bp del (Rv3540-Rv3550)
M-5 7 W79* (6)  A198P
600 M-1 1 N336K
M-2 5 R500* (5)
M-3 1 D49GM-4 2 C152R (2)
Note: * : stop codon: + or ins: insertion; - or del: deletion; no. in parenthesis next to a mutation: no. of isolates with the  same mutation.Gene name, amino acid (aa) length and no. of unique mutations s elected (n=54)certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 33 
 Table 2. Mutations identified in 64 individual colonies and poo led isolates of 
nitrioimidazole-resistant M. tuberculosis selected in C3HeB/FeJ mice 
Table 3. Distribution of mutation types and frequencies in gene s associated with 
pretomanid resistance, by mouse strain
 Pretomanid No. of
treatment Mouse single isolates Rv3261  (fbiA )Rv3262  (fbiB ) Rv1173  (fbiC ) Rv3547  (ddn ) Rv0407  (fgd1 ) Rv2983  (cofC )
(mg/kg) ID (n=64) 331aa (n=8) 448aa (n=1) 856aa (n=25) 151aa (n=7) 336aa (n=2) 214aa (n=2)
10 M-1 4 -A in aa 331;G194D; W198* A68E
M-2 4 -T in aa 353 -C in aa 363 +A in aa 214 (2)
M-3 2 -C in aa 20 L49P 
M-4 2 K684T Q114R
M-5 1 del 42 bp (aa 680-693)
30 M-1 5 -A in aa 225;+G in aa 107 (2) W27* 
IS6110 in 85bp upstream of  fbiC
M-2 5 -GC in aa 140 L377P (2); L377P (2, het, p)
M-4 3 G148D; W354R C149Y
M-5 3 G273D (2) 1 kb del (fbiC+PE12)
100 M-1 5 IS6110 ins. in aa 131 G191D (5)
M-2 1 del 4 bp in aa 75-76
M-3 3 -G in aa 47 (2) L685R
M-4 5 +C in aa 125 A588P (2): -G in aa 52; R322L
M-5 2 L308P (2)
300 M-1 5 A591D (2); A827G; +C in aa 328 (2)
M-2 5 Q120P (3) R322L; -T in aa 627
M-3 2 Q120P (2)
M-4 3 R112W (2); IS6110 ins. in D108
M-5 4 D286A T273K (2) -G in aa 39
Note: * : stop codon: + or ins: insertion; - or del: deletion; no. in parenthesis next to a mutation: no. of isolates with the  same mutation.Gene name, amino acid (aa) length and no. of unique mutations s elected (n=45)
Frequency
Rv3261 (fbiA )Rv3262 (fbiB )Rv1173 (fbiC )Rv3547 (ddn)Rv0407 (fgd1 )Rv2983 (cofC )No. of       of
331aa 448aa 856aa 151aa 336aa 214aa mutation  mutation
BALB/c no. of point mutation 4 3 15 0 2 6 30 56%
no. of indels (ins+del) 1 0 8 4 0 2 15 28%
no. of stop codon 2 0 6 1 0 0 9 17%
no. of total mutation 7 3 29 5 2 8 54 100%
frequency of mutation 13% 6% 54% 9% 4% 15% 100%
C3HeB/FeJ no of point mutation 5 0 12 31 2 2 3 5 1 %
no of indels (ins+del) 3 1 12 3 1 0 20 44%
no. of stop codon 0 0 1 1 0 0 2 4%
no. of total mutation 8 1 25 7 2 2 45 100%
frequency of mutation 18% 2% 56% 16% 4% 4% 100%
Note:  ins: insertion; del: deletion.Mouse 
modelType of mutationGene name and amino acid (aa) lengthcertified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 34 
 FIGURES
Fig. 1. Selective amplification of spontaneous pretomanid-resis tant mutants during
pretomanid monotherapy in mice is dose-dependent and is more pronounced in 
C3HeB/FeJ mice. After aerosol infection with M. tuberculosis H37Rv, BALB/c and C3HeB/FeJ
mice were treated with a range of doses of pretomanid for 8 weeks and sacrificed at different time points before and after treatment for lung CFU counts. A. Mean ( ¬± S.D.) total lung CFU counts on 
the day after infection (W-8), on the day of treatment initiation ( D0), and after 3 weeks of treatment 
with the indicated pretomanid dose (in mg/kg body weight). Dose -dependent bactericidal activity 
was observed in both strains; B. Mean (¬± S.D.) total and PMD-re sistant lung CFU counts in 
BALB/c mice on day 0 and after 8 weeks of treatment with the in dicated pretomanid dose. Dose-
dependent bactericidal activity and selection of PMD-resistant bacteria was observed, with the 
resistant population overtaking the susceptible population at d oses ¬ïPJNJ ; C. Mean (¬± S.D.)
total and PMD-resistant lung CFU counts in C3HeB/FeJ mice on da y 0 and after 8 weeks of 
treatment with the indicated pretomanid dose. Dose-dependent bactericidal activity and selection 
of PMD-resistant bacteria was observed, with the resistant popu lation overtaking the susceptible 
population at doses ¬ïPJNJ .* p < 0.05, *** p < 0.001
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 35 
 Fig. 2. Overall mutation frequencies of genes associated with pre tomanid resistance. WGS 
was performed with 136 pretomanid-resistant colonies and 25 colon y pools picked from 47 
individual mice harboring pretomanid-resistant CFU after 8 week s of treatment and identified 99
unique mutations in these 6 genes. Mutations in fbiC (55%) were the predominant cause of 
pretomanid resistance. For the other 5 genes, the rank order by mu tation frequency was 
fbiA(15%), ddn (12%), Rv2983 (10%), fgd1 (4%) and fbiB(4%).
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 36 
 E.
Fig. 3. Rv2983 is required for efficient F 420synthesis from Fo. F420and Fo content was 
measured in M. smegmatis strains harboring different recombinants relative to the contro l strain
containing the empty vector pYUBDuet after 6 (A) and 26 (B) hours of 1mM IPTG induction; F 420
(C) and Fo (D) content was measured in Rv2983 mutant strains of M. tuberculosis and control 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 37 
 strains including B101 ( ¬®Rv2983 , A198P), KA016 ¬®Rv2983 , Q114R), H37Rv (wild-type), B101
complemented strain (pMH94-Rv2983), B101 complemented strain (p MH94-hsp60- Rv2983 ), 
KA026 (¬®fbiC, IS6110 insertion in 85-bp upstream of fbiC), and K91 ( ¬®ddn, IS6110 insertion in aa
D108), after growth in 7H9 broth for 6 days. Schematic diagram (E)  of proposed nitroimidazole 
activation pathway showing Rv2983 as putative CofC catalyzing LPPG  biosynthesis. Fo, 7,8-
didemethyl-8-hydroxy-5-deazariboflavin; LP, 2-phospho-L-lactate ; GTP, guanosine triphosphate;
LPPG, L-lactyl-2-diphospho-5‚Äô-guanosine.certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 38 
 Fig. 4. F 420H2-deficient pretomanid- resistant mutants of M. tuberculosis are more 
susceptible to growth inhibition by malachite green. A. Growth of wild-type M. tuberculosis
on 7H9 agar is inhibited by malachite green (MG) in a concentratio n-dependent manner. F 420H2-
deficient, pretomanid-resistant M. tuberculosis mutants ( fbiA-C ,fgd1,Rv2983 ) are inhibited at 
lower MG concentrations relative to the wild type and the F 420H2-sufficient, pretomanid-resistant
ddnmutant. B-D. Complementation of the B101 mutant with wild-type Rv2983 restores tolerance 
to MG and the proportional recovery of the mutant on 6 Œºg/ml of MG increases as the duration of 
incubation increases from 28 (B), to 35 (C) to 49 (D) days of incub ation. The proportional recovery 
of the mutant on plates containing 12 Œºg/ml of MG does not incr ease with time.
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 39 
 Fig. 5. Mutation of Rv2983 causes growth inhibition and defective decolorization of 
malachite green. Aliquots (100 Œºl) of M. tuberculosis cultures (1, H37Rv wild type; 2, Rv2983 
mutant B101; 3, B101 mutant complemented with Rv2983 behind native promoter; 4, B101 
mutant complemented with Rv2983 behind hsp60 promoter) were spread on 7H9 agar plates 
containing increasing concentrations of malachite green (MG) aft er serial 10-fold dilutions. Colony
size and MG decolorization are depicted after different incubati on times. Numbers on plate labels 
(e.g., 0, 3, 4, 5) indicate the number of 10-fold dilutions perfo rmed before an aliquot was plated.
Although the B101 mutant grows more slowly on plates without MG , growth is further slowed in 
WKHSUHVHQFHRI¬ï¬óJPORI0*DQGWKHSURSRUWLRQRI&)8UHFRYHUHGGHFOLQHVZLWKLQFUHDVLQJ
MG concentrations above 0.25 Œºg/ml. For plates containing 6 and 1 2  Œº g / m l  o f  M G ,  p l a t e s  
receiving more-concentrated aliquots of the B101 mutant culture  are shown to demonstrate the 
markedly reduced recovery of the mutant at these MG concentrations.
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 40 
 C.
D.
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 41 
 Fig. 6.  Mutation of Rv2983 causes growth inhibition on commercial 7H10 agar and LJ 
slants, but not on commercial 7H11 agar. Aliquots of M. tuberculosis cultures were spread on 
various solid media purchased commercially after serial 10-fold dilutions. A-B. Mean CFU counts 
on 7H10 (A) and 7H11 (B) agar plates; C. Colonies on 7H10 agar plates after 21 (a) and 35 (b) 
days of incubation, and on 7H11 agar plates after 21 (c) days o f incubation; D. Colonies on LJ 
slants inoculated with serially diluted aliquots after 28 and 35 days of incubation. 1: H37Rv wild 
W\SH%PXWDQW¬® Rv2983 , A198P); 3: B101 mutant complemented with Rv2983 behind the 
native promoter; 4: B101 mutant complemented with Rv2983 behind the hsp60 promoter; 5. K91 
PXWDQW¬® ddn, IS6110 ins in D108).    
.certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 42 
 SUPPLEMENTARY MATERIALS
Table S1. List of the primers used in the study  
Table S2. WGS results for 136 individual pretomanid-resistant colonies se lected with different 
doses of pretomanid in M. tuberculosis -infected BALB/c and C3HeB/FeJ mice  
Table S3. WGS results for 25 pooled pretomanid-resistant isolates selecte d with different doses 
of pretomanid in M. tuberculosis -infected BALB/c and C3HeB/FeJ mice
Table S4. Distribution of overall mutation types and frequencies in genes  associated with 
pretomanid resistance 
Table S5. Pretomanid MICs against selected pretomanid-resistant M. tuberculosis mutants
Figure S1. Complementation of B101 mutant with Rv2983 . A. Schematic diagram of genomic 
DNA of M. tuberculosis strains after digestion with restriction enzyme Acc65I; B. Resu lt of 
southern blot confirmed expected DNA fragments after Acc65I dig estion using DIG-labeled 
Rv2983 probe (H37Rv: 6.3 kb; Rv2983 mutant: 6.3 kb; complemented strain s: 6.3 and 3.5 kb).
Figure S2. Expression of Rv2983 and other genes involved in nitroimidazole activation. A. 
Expression of Rv2983 and other genes involved in nitroimidazole activation is higher  i n  t h e  
Rv2983 mutant B101 relative to the wild-type H37Rv after 4 days of incu bation in 7H9 broth; B. 
fbiC expression is dramatically lower in the fbiC mutant KA026 relative to the wild-type after 2 
days of incubation in 7H9 broth; C. A faint band representing t he 937-bp fbiC DNA fragment is 
evident in the sample from the KA026 mutant (lane 2) relative t o that in H37Rv (lane 3). Lane 1 
is the 1-kb DNA marker. 
Figure S3. Complementation of the B101 mutant with wild-type Rv2983 restores tolerance to MG. 
The proportional recovery of the mutant on 6 Œºg/ml of MG increas es with the volume of culture 
plated and the duration of incubation: 28-day incubation of 500 Œºl (A) aliquots/plate; 35-day 
incubation of 500 Œºl (B) aliquots/plate. certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 43 
 SUPPLEMENTARY MATERIALS
Table S1. List of the primers used in the study  
Table S2. WGS results for 136 individual p retomanid-resistant colonies se lected with different 
doses of pretomanid in M. tuberculosis -infected BALB/c and C3HeB/FeJ mice  Primer name  Primer sequence Purpose of amplification
Rv2983 -1F GCTCGGTACCCGGGGATCCTCCCAAGTGCCTCCTCGGC Rv2983  OFR and flanking sequences
Rv2983 -1R GGTGCCCTTGGTGGTCGACTGTTCGCCGTTGGTCTGCC
hsp60 - F GCTCGGTACCCGGGGATCCTTCGGCCATGACAAGAATCTG hsp60  promoter
hsp60 - R TGCCGCTCATGCATGTTTGGGCGCATCC
Rv2983 - 2F CCAAACATGCATGAGCGGCACACCGGAC Rv2983  ORF
Rv2983 - 2R GGTGCCCTTGGTGGTCGACTTCAACGATGTGCGACCGC
Rv2983 - 3F GACTCGCGAGAACGTGGT Rv2983  DNA probe
Rv2983 - 3R CCAGGCTCCTGTCAGCTC
Rv2983 - 4F GTATAAGAAGGAGATATACAATGAGCGGCACACCGGAC Rv2983  ORF
Rv2983 - 4R TGGCAGCAGCCTAGGTTAATTCAACGATGTGCGACCGC
Rv2983 -RT-F CGATTTGCCGGCATTACAGA expression of Rv2983 
Rv2983 -RT-R CGAACGCACACAGTACCG
fbiC-RT-F GTCCATTCCGTTTACCACCG expression of fbiC
fbiC-RT-R CGGAAGTTCTGCACGATCAC
fbiA-RT-1F        CCAGTTTGCTGCCAATTCTG expression of fbiA
fbiA-RT-1R        ACATGCAGGTGTCCAGATCC
fbiB-RT-F GGATGAAAGACAAGTGGCGG expre ssion of fbiB
fbiB-RT-R ACTTCGGGTGCGTCATAGAG
fgd1-RT-F GTACCCGAACCGTGTTTTCC expression of fgd1
fgd1-RT-R CATTAGCCCCACCGATTCAC
sigA- F CTACGCTACGTGGTGGATTC expression of sigA
sigA-R GGTGATGTCCATGTCTTTGG 
fbiC-5-7_F GCAAGGTGTTTATCCCGGTC fbiC DNA fragment
fbiC-5-7_R TGTACGTATTTGGGTTGCGCcertified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 44 
 Pretomanid Pretomanid
Mouse treatment dose Mouse  selection concentration Name of  Sample Sequencing Rv3261 (fbiA ) Rv3262 (fbiB ) Rv1173 (fbiC ) Rv3547 (ddn ) Rv0407 (fgd1 ) Rv2983 (cofC )
model (mg/kg) ID (Œºg/ml) isolates ID (DNA) coverage 331aa (n=24, 17.6%) 448aa (n=4, 2.9%) 856aa (n=77, 56.6%) 151aa (n=9, 6.6%) 336aa (n=5, 3.7%) 214aa (n=17, 12.5%)
BALB/c 0 M-1 0.25 BA_002 1963 37.2 K9N
1 BA_003 1964 37.9 -G in aa 38 NuoM:P26S
M-2 0.25 BA_004 1965 35.1 -A in aa 503 PPE31:S12L; gabT:L361V
0.25 BA_005 1966 39.6 R133P
0.25 BA_006 1967 32.7 R133P
10 BA_007 1968 57.7 K9N Rv3235:G41D
M-4 1 BA_009 1969 46.5 W690*
M-5 0.25 BA_010 1970 27 +A in aa 426
1 BA_011 1971 49.2 +A in aa 426
10 BA_012 1972 49.5 +A in aa 426
10 BA_013 1973 39.2 +A in aa 426
10 M-1 0.25 BA_014 1974 41.6 L702R
0.25 BA_015 1975 54.9 L702R
1 BA_016 1976 45.6 L702R
10 BA_017 1977 40.5 C562W
10 BA_018a 1978 42 L702R
10 BA_019a 1979 28.5 +C in aa 27 citA:R293R; cya:V141F; Rv3541c:V108V; Rv3689:Q425R
M-2 0.25 BA_020 1980 56.8 9 bp del (aa 307-309)
0.25 BA_021 1981 43.7 -GC in aa 39
1 BA_022 1982 53.6 A212V nc230580:G>A
10 BA_024 1984 76 -TCCCCGATG, del aa 306-308
M-3 0.25 BA_025 1985 93.9 -C in aa 252 fadD24:A364A
0.25 BA_026a 1986 87.1 L15P Rv1230c:C360G; trpA:Y35C; cycA:T433A; hflx:L435P
10 BA_028 1988 59 -C in aa 252 fadD24:A364A
10 BA_029 1989 49.5 L772W Rv3254:A225S; Rv3805c:A417A
M-4 1 BA_031 1991 93.9 G147C Rv3254:A225S; Rv3805c:A417A
1 BA_032 1992 83.7 G147C Rv3254:A225S; Rv3805c:A417A
10 BA_033 1993 114.2 G147C Rv3254:A225S; Rv3805c:A417A
M-5 0.25 BA_035 1995 80 A632V fprB:V58F; secD:T232S
1 BA_036 1996 47.8 R25G
30 M-1 10 BA_041 2001 28.3 S169P Rv3792:V600F
M-2 0.25 BA_043 2003 50.8 A132V
1 BA_044 2004 44.9 W20* Rv1230c:C360G; trpA:Y35C; cycA:T433A
10 BA_045 2005 47.9 L211P ppsB:A354S
M-3 1 BA_048 2008 37.9 R278P Rv1129c:Y301Y; Rv1314c:P80P
1 BA_049a 2009 69.3 R278P Rv1129c:Y301Y; Rv1314c:P80P
M-4 10 BA_053 2013 49 W155* Rv3792:V600F
M-5 0.25 BA_055 2015 66.5 Q400* Rv1230c:C360G; nc3134222:C>T (41 bp downstream from Rv2825c)
10 BA_058 2017 77.8 +T in aa 188 Rv1871c:G48D
10 BA_059 2018 60.7 +T in aa 188 Rv1871c:G48D
100
M-1 0.25 BA_060 2019 65.8 -ATC in aa 129 Rv3792:V600F
M-2 0.25 BA_062 2021 75.6 K682E Rv1230c:C360G
10 BA_064 2023 72.4 Y170* Rv1931c:A172A
10 BA_065 2024 56.5 L187R Rv0609A:G64S; rc789981:GG>AC; Rv2969c:S132A
M-3 10 BA_069 2028 66.5 W397R Rv3254:A225S; Rv3805c:A417A
10 BA_070 2029 75.2 L173P mprB:A491A; nadB:P332S; nc2639032:C>T (24bp downstream from PPE 40)
M-4 1 BA_071 2030 74.9 F744S
10 BA_072 2031 61.2 -C in aa 93
M-5 0.25 BA_074a 2033 69.6 S219G bioF2:C450F
1 BA_075 2034 67.4 M776T fadD24:A364A; Rv1749c:W171R
10 BA_076 2035 59.7 M776T fadD24:A364A; Rv1749c:W171R
10 BA_077 2036 64.3 M776T fadD24:A364A; Rv1749c:W171R
300 M-1 1 BA_078 2037 55 R25S NarK3:A338A
1 BA_079 2038 76.8 R25S NarK3:A338A
1 BA_080 2039 92.3 R25S NarK3:A338A
10 BA_081a 2040 125.5 R25S NarK3:A338A
10 BA_082 2041 86.9 R25S NarK3:A338A
M-2 1 BA_084 2043 77.5 Q27* Rv0312:P510A, citA:R293R, Rv3541c:V108V, plus 3 other heterogeneous sites
10 BA_086a 2045 62.3 -G in aa 248 Rv0102:Y176Y'; Rv0579:L142P; Rv1230c:C360G
10 BA_087 2046 49.1 Q27* Rv0312:P510A; citA:R293R; Rv3541c:V108V
M-3 0.25 BA_089 2048 78.3 H190N nc3383560:G>A
1 BA_090 2049 75.9 -GC in aa 846
10 BA_091 2050 56.3 -GC in aa 846
10 BA_092 2051 85.2 Q20* fadE4:K33R(het)
M-4 0.25 BA_093 2052 85.3 T707M
1 BA_095 2054 45.1 9345 bp del (Rv3540-Rv3550) Rv2993c:P56Q
10 BA_096 2055 84.3 T301A Rv2993c:P56Q
10 BA_097 2056 97.7 -C in aa 247 nc4020443:C>A (2bp downstream. of lppH)
M-5 0.25 BA_098 2057 100.8 W79*
0.25 BA_099 2058 77 W79*
0.25 BA_100 2059 112.9 W79*
1B A_101 2 060 7 6.2 A198P
1 BA_102 2061 57.9 W79*
600 M-1 1 BA_103 2062 43.8 N336K
M-2 0.25 BA_106a 2063 100.8 R500* pks7:V338L; lipN:C976G; lipN:I96R
0.25 BA_107 2064 78.6 R500* pks7:V338L; lipN:C976G; lipN:I96R
1 BA_108 2065 60.9 R500* pks7:V338L; lipN:C976G; lipN:I96R
10 BA_109 2066 81.8 R500* pks7:V338L; lipN:C976G; lipN:I96R
10 BA_110 2067 90.2 R500* pks7:V338L; lipN:C976G; lipN:I96R
M-3 10 BA_114 2071 63.5 D49G
M-4 10 BA_119 2076 47.7 C152R Rv3090:S254S
10 BA_120 2077 76.1 C152R Rv3090:S254S
C3HeB/FeJ 10 M-1 1 KA_001 1873 32.3 -A in aa 331 nrp:V1705A, pknD:T633N
1 KA_003 1875 27.6 A68E atpH:A439E;Rv2009:E12D
10 KA_004 1876 23.1 G194D
10 KA_005 1877 42.2 W198*
M-2 1 KA_006 1878 39.2 -T in aa 353 nirB:V29A, xseA:V202V, nc3382560:G>A, Rv3242c:L73R
1 KA_008 1879 87.2 +A in aa 214
10 KA_009 1880 58.8 -C in aa 363 lpqM:G3G
10 KA_010 1881 84.7 +A in aa 214
M-3 10 KA_014 1885 29.8 -C in aa 20
M-4 0.25 KA_016 1887 94 Q114R Rv0686:T90A; Rv3792:V600F
1 KA_017 1888 81.8 K684T fadE7:L103V; Rv1347c:F143L
M-5 0.25 KA_022 1892 91.1 del 42 bp (aa 680-693) nc3382560:G>A
30 M-1 1 KA_026a 1896 41.9 IS6110 in 85bp upstream of fbiC Rv0628c:A 310S; Rv1975:A170S
1 KA_028 1898 57.3 -A in aa 225 nadB:P332S
10 KA_029 1899 36.5 +G in aa 107
10 KA_030 1900 43.6 +G in aa 107
M-2 1 KA_031 1901 40.6 L377P R3831:P23P
1 KA_032 1902 88.5 L377P R3831:P23P
10 KA_034 1904 33.1 -GC in aa 140 R3831:P23P
M-4 0.25 KA_037 1907 85.9 G148D Rv1230c:C360G; lipB:D101E
1 KA_039 1909 82.2 W354R Rv1230c:C360G
M-5 0.25 KA_041 1911 103.7 1 kb del (fbiC+PE12)
0.25 KA_043 1913 122.8 G273D lppN:L9F; Rv0669c:Q537R(53%)
1 KA_044 1914 42.1 G273D lppN:L9F
100 M-1 1 KA_047 1916 34.8 IS6110 ins. in aa 131 cobN:M1045I
10 KA_050 1919 83.3 G191D
M-2 0.25 KA_052 1921 94.9 del 4 bp in aa 75-76 ctpE:A448A; Rv1685c:T188N
M-3 1 KA_057 1926 40.3 L685R pta:L406R; uvrD1:D273D
1 KA_058 1927 33.4 -G in aa 47
10 KA_059 1928 107.8 -G in aa 47
M-4 0.25 KA_061 1930 31.5 A588P mca:T113A
0.25 KA_062 1931 94.5 -G in aa 52 alkB:Y391D
1 KA_063 1932 37.8 R322L pks7:V338L; Rv3312A:D67H
10 KA_064 1933 35.4 +C in aa 125 mca:T113A
10 KA_065 1934 93.2 A588P mca:T113A;Rv2817c:A280A
M-5 10 KA_067 1961 42.2 L308P Rv0609A:G64S; nc789981:GG>AC 45 bp downstream from Rv0690c; Rv2 969c:S132A
1 KA_068 1936 97.4 L308P Rv0609c:G64S; nc789981:GG>AC; Rv2969c:S132A
300 M-1 0.25 KA_071 1939 40.6 A591D xseA:D388E
0.25 KA_072 1940 96.2 +C in aa 328 pknI:L455R
0.25 KA_073 1941 45.5 A827G
1 KA_074 1942 53.4 A591D xseA:D388E
1 KA_075 1943 45.7 +C in aa 328 pknI:L455R
M-2 0.25 KA_076 1944 102.8 R322L pks7:V338L; Rv3312A:D67H
1 KA_078 1946 75.1 -T in aa 627
1 KA_079 1947 69.2 Q120P acrA1:R161C; -G in PPE13 (9 aa from C-term); Rv3168:A182T
10 KA_080 1948 73.8 Q120P -G in PPE13 (9 aa from C-term)
10 KA_081 1949 211.2 Q120P Rv0285/PE5:V63G
M-3 10 KA_085 1951 111.4 Q120P acrA1:R161C; -G in PPE13 (9 aa from C-term)
M-4 0.25 KA_088a 1953 41.5 R112W
1 KA_091 1955 63 IS6110 ins. in D108
M-5 1 KA_093 1957 194.5 -G in aa 39 nuoM:P26S
1 KA_094 1958 44 T273K Rv2842c:V153V
10 KA_095 1959 119.4 T273K Rv2842c:V153V
10 KA_096 1960 119.7 D286A Rv3867:D47N
Note: aa: amino acid;  n: number of isolate and isolation rate among all the individule isolates; * : stop codon: +: insertion; -: deletion; ins: insertion: del: deletion; unknown: no mutat ion found in the six genes; >: substitution.   Gene name, amino acid length and no. of isolates (n=136, 100%)
Other mutationscertified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 45 
 Table S3. WGS results for 25 pooled pretomanid-resistant isolates selecte d with different doses 
of pretomanid in M. tuberculosis -infected BALB/c and C3HeB/FeJ mice
Table S4. Distribution of overall mutation types and frequencies in genes  associated with 
pretomanid resistance Pretomanid Pretomanid Name of 
Mouse treatment dose Mouse  selection concentration pooled  Sample Sequencing Rv3261 (fbiA)Rv3262 (fbiB)Rv1173 (fbiC)Rv3547 (ddn)Rv0407 (fgd1)Rv2983 (cofC)
model (mg/kg) ID (Œºg/ml) isolates ID (DNA) coverage 331aa 448aa 856aa 151aa 336aa 214aa
Balbc 10 M-4 1 P1 2084 103.4 G147C Rv3254:A225S; Rv3805c:A417A
10 P2 2085 140.3 G147C Rv3254:A225S; Rv3805c:A417A
300 M-1 1 P3 2086 123.1 R25S narK3:A338A(het)
10 P4 2087 74.5 R25S(het) narK3:A338A(het)
M-2 10 P6 2089 44.6 Q27*(het) Rv3541c:V108V; Rv0312:P510A(het); citA:R293R(het)
M-5 0.25 P7 2090 44.6 W79*
1 P8 2091 67.8 W79*
600 M-5 1 P9 2092 55.3 Rv2310:E94A; Rv3792:V600F(het); proS:A524E(het)
C3HeB/FeJ 10 M-1 10 P11 2094 39.5 nrp:V1705A; pknD:T633N
M-3 1 P12 2095 34.4 L49P(het)
30 M-1 1 P13 2096 65.9 W27*(het) Rv0628c:A310S(het); Rv1975:A170S(het)
10 P14 2097 66.2 Rv0628c:A310S(het); Rv1975:A170S(het)
M-2 1 P15 2098 35.5 L377P(het) Rv3831:P23P
10 P16 2099 53.1 L377P(het) Rv3831:P23P
M-4 0.25 P17 2100 53 C149Y(het) Rv1230c:C360G(het); ureG:L58L(het); Rv2567:A728A(het); Rv3229c:T133A(het); nadB:P322S(het); Rv3447c: het
1 P18 2101 67.7 Rv1230c:C360G(het); ureG:L58L(het); Rv2567:A728A(het); Rv3229c:T133A(het);nadB:P322S(het)
100 M-1 0.25 P19 2102 73 G191D(het) cobN:M1045I(het); groEL:G171G(het)
1 P20 2103 33.8 G191D(het) cobN:M1045I(het); groEL:G171G(het); Rv0987:indel?
10 P21 2104 75 G191D(het) groEL:G171G(het)
M-4 1 P24 2107 48.6
300 M-1 1 P26 2108 44.4 pknI:L455R(het)
M-3 1 P27 2109 30.8 Q120P(het)
M-4 0.25 P28 2110 93.4 R112W(het)
1 P29 2111 142.9
M-5 10 P31 2113 139.5
Note: * : stop codon; het: heterogeneous. Gene name and amino acid (aa) length 
Other mutations
Frequency
Rv3261 (fbiA )Rv3262 (fbiB )Rv1173 (fbiC )Rv3547 (ddn)Rv0407 (fgd1 )Rv2983 (cofC )  No. of       of
331aa 448aa 856aa 151aa 336aa 214aa mutation   mutation
no. of point mutation 9 3 27 3 3 8 53 54%
no. of indels (ins+del) 4 1 20 7 1 2 35 35%
no. of stop codon 2 0 7 2 0 0 11 11%
no. of total mutation 15 4 54 12 4 10 99 100%
frequency of mutation 15% 4% 55% 12% 4% 10% 100%
Note:  ins: insertion; del: deletion.Type of mutationGene name and amino acid (aa) lengthcertified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 46 
 Table S5. Pretomanid MICs against selected pretomanid-resistant M. tuberculosis mutants   
Mouse Isolate Pretomanid treatment Pretomanid selection Gene Mutati on  Agar-based MIC Broth-based MIC
model  dose (mg/kg) concentration (Œºg/ml ) (Œºg/ml)   (Œºg/ml)
H37Rv parent wild-type 0.06 0.25
BALB/c BA_002 0 0.25 fgd1 K9N >32
BA_016 10 1 fbiC L702R >32
BA_101 300 1 Rv2983 A198P 32
C3HeB/FeJ KA_006 10 1 fbiB del of T684 8
KA_058 100 1 fbiA del of G47 >32
KA_091 300 1 ddn D108 (IS6110 ins) 32
KA-016 10 0.25 Rv2983 Q114R >32
KA-026a 30 1 fbiC IS6110 ins. in 85bp upstream of fbiC >32certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 47 
 Figure S1. Complementation of B101 mutant with Rv2983 . A. Schematic diagram of genomic 
DNA of M. tuberculosis strains after digestion with restriction enzyme Acc65I; B. Resu lt of 
southern blot confirmed expected DNA fragments after Acc65I digestion using DIG-labeled 
Rv2983 probe (H37Rv: 6.3 kb; Rv2983 mutant: 6.3 kb; complemented strai ns: 6.3 and 3.5 kb).
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 48 
 Figure S2. Expression of Rv2983 and other genes involved in nitroimidazole activation. A. 
Expression of Rv2983 and other genes involved in nitroimidazole activation is higher  i n  t h e  
Rv2983 mutant B101 relative to the wild-type H37Rv after 4 days of inc ubation in 7H9 broth; B. 
fbiC expression is dramatically lower in the fbiC mutant KA026 relative to the wild-type after 2 
days of incubation in 7H9 broth; C. A faint band representing t he 937-bp fbiC DNA fragment is 
evident in the sample from the KA026 mutant (lane 2) relative t o that in H37Rv (lane 3). Lane 1 
is the 1-kb DNA marker. 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 49 
 Figure S3. Complementation of the B101 mutant with wild-type Rv2983 restores tolerance to MG. 
The proportional recovery of the mutant on 6 Œºg/ml of MG increa ses with the volume of culture 
plated and the duration of incubation: 28-day incubation of 500 Œºl (A) aliquots/plate; 35-day 
incubation of 500 Œºl (B) aliquots/plate. 
certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 50 
 certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which was not this version posted October 31, 2018. ; https://doi.org/10.1101/457754doi: bioRxiv preprint 